ANI Pharmaceuticals (ANIP) 10-Q9 Nov 222022 Q3 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2022	Nov. 02, 2022
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-31812
Entity Registrant Name	ANI PHARMACEUTICALS, INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	58-2301143
Entity Address, Address Line One	210 Main Street West
Entity Address, City or Town	Baudette
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	56623
City Area Code	218
Local Phone Number	634-3500
Title of 12(b) Security	Common Stock
Trading Symbol	ANIP
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Central Index Key	0001023024
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false
Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		17,453,805
Class C Special Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		10,864

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents	$ 56,281	$ 100,300
Accounts receivable, net of $111,000 and $105,260 of adjustments for chargebacks and other allowances at September 30, 2022 and December 31, 2021, respectively	140,433	128,526
Inventories, net	95,893	81,693
Prepaid income taxes	3,778	3,667
Assets held for sale	8,020
Prepaid expenses and other current assets	4,972	7,589
Total Current Assets	309,377	321,775
Property and equipment	72,935	75,627
Accumulated depreciation	(30,105)	(22,956)
Property and equipment, net	42,830	52,671
Restricted cash	5,003	5,001
Deferred tax assets, net of deferred tax liabilities and valuation allowance	77,340	67,936
Intangible assets, net	264,237	294,122
Goodwill	28,221	27,888
Derivatives and other non-current assets	12,102	2,205
Total Assets	739,110	771,598
Current Liabilities
Current debt, net of deferred financing costs	850	850
Accounts payable	18,992	22,967
Accrued royalties	6,585	6,225
Accrued compensation and related expenses	7,745	8,522
Accrued government rebates	8,745	5,492
Returned goods reserve	33,984	35,831
Accrued expenses and other	4,726	7,650
Total Current Liabilities	81,627	87,537
Non-current Liabilities
Non-current debt, net of deferred financing costs and current component	285,882	286,520
Non-current contingent consideration	33,434	31,000
Derivatives and other non-current liabilities	1,492	7,801
Total Liabilities	402,435	412,858
Commitments and Contingencies (Note 13)
Mezzanine Equity
Convertible Preferred Stock, Series A, $0.0001 par value, 1,666,667 shares authorized; 25,000 shares issued and outstanding at September 30, 2022 and December 31, 2021	24,850	24,850
Stockholders' Equity
Common Stock, $0.0001 par value, 33,333,334 shares authorized; 17,613,771 shares issued and 17,467,920 outstanding at September 30, 2022; 16,912,401 shares issued and 16,829,739 shares outstanding at December 31, 2021	1	1
Class C Special Stock, $0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively
Preferred Stock, $0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively
Treasury stock, 145,851 shares of common stock, at cost, at September 30, 2022 and 82,662 shares of common stock, at cost, at December 31, 2021	(4,975)	(3,135)
Additional paid-in capital	399,396	387,844
Accumulated deficit	(92,636)	(47,765)
Accumulated other comprehensive income/(loss), net of tax	10,039	(3,055)
Total Stockholders' Equity	311,825	333,890
Total Liabilities, Mezzanine Equity, and Stockholders' Equity	$ 739,110	$ 771,598

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Adjustments for chargebacks and other allowances	$ 111,000	$ 105,260
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	1,666,667	1,666,667
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Treasury Stock, Common, Shares	145,851	82,662
Convertible Preferred Stock
Convertible Preferred Stock, Par Value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible Preferred Stock, Shares Authorized	1,666,667	1,666,667
Convertible Preferred Stock, Shares Issued	25,000	25,000
Convertible Preferred Stock, Shares Outstanding	25,000	25,000
Common Stock
Common Stock, Par Value (in dollars per share)	$ 0.0001	$ 0.0001
Common Stock, Authorized Shares	33,333,334	33,333,334
Common Stock, Issued Shares	17,613,771	16,912,401
Common Stock, Outstanding Shares	17,467,920	16,829,739
Class C Special Stock
Common Stock, Par Value (in dollars per share)	$ 0.0001	$ 0.0001
Common Stock, Authorized Shares	781,281	781,281
Common Stock, Issued Shares	10,864	10,864
Common Stock, Outstanding Shares	10,864	10,864

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Condensed Consolidated Statements of Operations
Net Revenues	$ 83,821	$ 52,061	$ 222,153	$ 155,207
Operating Expenses
Cost of sales (excluding depreciation and amortization)	32,894	24,413	102,459	66,712
Research and development	7,657	2,456	17,096	8,229
Selling, general, and administrative	30,081	17,181	90,856	53,588
Depreciation and amortization	14,167	11,346	42,488	33,568
Contingent consideration fair value adjustment	2,476		2,134	0
Legal settlement expense			0	8,400
Purified Cortrophin Gel pre-launch charges		227	0	780
Restructuring activities	1,541		4,111	0
Intangible asset impairment charge		0	112	0
Total Operating Expenses	88,816	55,623	259,256	171,277
Operating Loss	(4,995)	(3,562)	(37,103)	(16,070)
Other Expense, net
Interest expense, net	(7,264)	(2,497)	(20,546)	(7,482)
Other income/(expense), net	37	(1,071)	712	(1,653)
Loss Before Benefit for Income Taxes	(12,222)	(7,130)	(56,937)	(25,205)
Benefit for income taxes	3,622	2,683	13,284	6,738
Net Loss	(8,600)	(4,447)	(43,653)	(18,467)
Dividends on Series A Convertible Preferred Stock	(406)		(1,218)	0
Net Loss Available to Common Shareholders	$ (9,006)	$ (4,447)	$ (44,871)	$ (18,467)
Basic and Diluted Loss Per Share:
Basic Loss Per Share	$ (0.55)	$ (0.37)	$ (2.76)	$ (1.53)
Diluted Loss Per Share	$ (0.55)	$ (0.37)	$ (2.76)	$ (1.53)
Basic Weighted-Average Shares Outstanding	16,303	12,107	16,238	12,066
Diluted Weighted-Average Shares Outstanding	16,303	12,107	16,238	12,066

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income/(Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Condensed Consolidated Statements of Comprehensive Income/(Loss)
Net loss	$ (8,600)	$ (4,447)	$ (43,653)	$ (18,467)
Other comprehensive income/(loss), net of tax:
Gains on interest rate swap, net of tax	4,609	1,198	13,094	7,202
Total other comprehensive income, net of tax	4,609	1,198	13,094	7,202
Total comprehensive loss, net of tax	$ (3,991)	$ (3,249)	$ (30,559)	$ (11,265)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Class C Special Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive (Loss)/Gain, Net of Tax	Accumulated Deficit	Total
Balance at Dec. 31, 2020	$ 1		$ 214,354	$ (2,246)	$ (11,437)	$ (4,972)
Beginning Balance, Common (in shares) at Dec. 31, 2020	12,430,000
Beginning Balance, Treasury (in shares) at Dec. 31, 2020				76,000
Beginning balance, permanent and temporary equity at Dec. 31, 2020							$ 195,700
Increase (decrease) in Stockholders' Equity
Stock-based Compensation Expense			7,521				7,521
Treasury Stock Purchases for Restricted Stock Vests				$ (889)			(889)
Treasury Stock Purchases for Restricted Stock Vests (in shares)				28,000
Issuance of Restricted Stock Awards (in shares)	463,000
Issuance of Common Shares upon Stock Option and ESPP Exercise			336				336
Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares)	12,000
Restricted Stock Awards Forfeitures (in shares)	(81,000)			(21,000)
Other Comprehensive Income					7,202		7,202
Net Loss						(18,467)	(18,467)
Ending balance, permanent and temporary equity at Sep. 30, 2021							191,403
Balance at Sep. 30, 2021	$ 1		222,211	$ (3,135)	(4,235)	(23,439)
Ending Balance, Common (in shares) at Sep. 30, 2021	12,824,000
Ending Balance, Treasury (in shares) at Sep. 30, 2021				83,000
Balance at Jun. 30, 2021	$ 1		219,403	$ (3,062)	(5,433)	(18,992)
Beginning Balance, Common (in shares) at Jun. 30, 2021	12,826,000
Beginning Balance, Treasury (in shares) at Jun. 30, 2021				80,000
Beginning balance, permanent and temporary equity at Jun. 30, 2021							191,917
Increase (decrease) in Stockholders' Equity
Stock-based Compensation Expense			2,808				2,808
Treasury Stock Purchases for Restricted Stock Vests				$ (73)			(73)
Treasury Stock Purchases for Restricted Stock Vests (in shares)				3,000
Issuance of Restricted Stock Awards (in shares)	6,000
Restricted Stock Awards Forfeitures (in shares)	(8,000)
Other Comprehensive Income					1,198		1,198
Net Loss						(4,447)	(4,447)
Ending balance, permanent and temporary equity at Sep. 30, 2021							191,403
Balance at Sep. 30, 2021	$ 1		222,211	$ (3,135)	(4,235)	(23,439)
Ending Balance, Common (in shares) at Sep. 30, 2021	12,824,000
Ending Balance, Treasury (in shares) at Sep. 30, 2021				83,000
Balance at Dec. 31, 2021	$ 1		387,844	$ (3,135)	(3,055)	(47,765)	$ 333,890
Beginning Balance, Common (in shares) at Dec. 31, 2021	16,913,000
Beginning Balance, Treasury (in shares) at Dec. 31, 2021				83,000			82,662
Beginning balance, permanent and temporary equity at Dec. 31, 2021							$ 358,740
Increase (decrease) in Stockholders' Equity
Stock-based Compensation Expense			10,862				10,862
Treasury Stock Purchases for Restricted Stock Vests				$ (1,840)			(1,840)
Treasury Stock Purchases for Restricted Stock Vests (in shares)				63,000
Issuance of Restricted Stock Awards (in shares)	723,000
Issuance of Common Shares upon Stock Option and ESPP Exercise			690				690
Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares)	24,000
Dividends on Series A Convertible Preferred Stock						(1,218)	(1,218)
Restricted Stock Awards Forfeitures (in shares)	(46,000)
Other Comprehensive Income					13,094		13,094
Net Loss						(43,653)	(43,653)
Ending balance, permanent and temporary equity at Sep. 30, 2022							336,675
Balance at Sep. 30, 2022	$ 1		399,396	$ (4,975)	10,039	(92,636)	$ 311,825
Ending Balance, Common (in shares) at Sep. 30, 2022	17,614,000	11,000
Ending Balance, Treasury (in shares) at Sep. 30, 2022				146,000			145,851
Balance at Jun. 30, 2022	$ 1		395,043	$ (4,736)	5,430	(83,630)
Beginning Balance, Common (in shares) at Jun. 30, 2022	17,566,000
Beginning Balance, Treasury (in shares) at Jun. 30, 2022				139,000
Beginning balance, permanent and temporary equity at Jun. 30, 2022							$ 336,958
Increase (decrease) in Stockholders' Equity
Stock-based Compensation Expense			3,870				3,870
Treasury Stock Purchases for Restricted Stock Vests				$ (239)			(239)
Treasury Stock Purchases for Restricted Stock Vests (in shares)				7,000
Issuance of Restricted Stock Awards	$ 0	$ 0	0	$ 0	0	0	0
Issuance of Restricted Stock Awards (in shares)	54,000
Issuance of Common Shares upon Stock Option and ESPP Exercise			483				483
Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares)	16,000
Dividends on Series A Convertible Preferred Stock						(406)	(406)
Restricted Stock Awards Forfeitures (in shares)	(22,000)
Other Comprehensive Income					4,609		4,609
Net Loss						(8,600)	(8,600)
Ending balance, permanent and temporary equity at Sep. 30, 2022							336,675
Balance at Sep. 30, 2022	$ 1		$ 399,396	$ (4,975)	$ 10,039	$ (92,636)	$ 311,825
Ending Balance, Common (in shares) at Sep. 30, 2022	17,614,000	11,000
Ending Balance, Treasury (in shares) at Sep. 30, 2022				146,000			145,851

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity-Mezzanine - USD ($) $ in Thousands	Convertible Preferred Stock	Total
Balance at Dec. 31, 2021	$ 24,850	$ 24,850
Balance (in shares) at Dec. 31, 2021	25,000
Balance at Sep. 30, 2022	$ 24,850	24,850
Balance (in shares) at Sep. 30, 2022	25,000
Balance at Jun. 30, 2022	$ 24,850
Balance (in shares) at Jun. 30, 2022	25,000
Increase (decrease) in temporary equity
Issuance of Restricted Stock Awards	$ 0	0
Issuance of Restricted Stock Awards (in shares)	0
Balance at Sep. 30, 2022	$ 24,850	$ 24,850
Balance (in shares) at Sep. 30, 2022	25,000

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flows From Operating Activities
Net loss	$ (43,653)	$ (18,467)
Adjustments to reconcile net loss to net cash and cash equivalents (used in)/provided by operating activities:
Stock-based compensation	10,862	7,521
Deferred taxes	(13,628)	(8,665)
Depreciation and amortization	44,081	33,568
Acquired in-process research and development ("IPR&D")	1,151	0
Non-cash interest	2,963	1,718
Contingent consideration fair value adjustment	2,134	0
Asset impairment charges	574	0
Gain on sale of ANDAs	(750)	0
Changes in operating assets and liabilities:
Accounts receivable, net	(11,907)	(10,921)
Inventories, net	(14,164)	8,773
Prepaid expenses and other current assets	2,617	1,421
Accounts payable	(5,027)	396
Accrued royalties	360	(2,411)
Current income taxes payable, net	(111)	(6,936)
Accrued government rebates	3,253	3,887
Returned goods reserve	(1,818)	5,091
Accrued expenses, accrued compensation, and other	(3,740)	532
Net Cash and Cash Equivalents (Used in)/Provided by Operating Activities	(26,803)	15,507
Cash Flows From Investing Activities
Acquisition of Novitium Pharma LLC, net of cash acquired	(33)	0
Acquisition of product rights, IPR&D, and other related assets	(7,575)	(21,069)
Acquisition of property and equipment, net	(5,738)	(2,201)
Proceeds from the sale of long-lived assets	750	0
Net Cash and Cash Equivalents Used in Investing Activities	(12,596)	(23,270)
Cash Flows From Financing Activities
Payments on borrowings under credit agreements	(2,250)	(8,034)
Borrowings under Prior Revolver agreement	0	24,000
Series A convertible preferred stock dividends paid	(1,218)	0
Proceeds from stock option exercises and ESPP purchases	690	336
Payments of debt issuance costs	0	(262)
Treasury stock purchases for restricted stock vests	(1,840)	(889)
Net Cash and Cash Equivalents (Used in)/Provided by Financing Activities	(4,618)	15,151
Net Change in Cash and Cash Equivalents	(44,017)	7,388
Cash and cash equivalents, beginning of period	105,301	12,867
Cash and cash equivalents, end of period	61,284	20,255
Reconciliation of cash, cash equivalents, and restricted cash, beginning of period
Cash and cash equivalents	100,300	7,864
Restricted cash	5,001	5,003
Cash and cash equivalents, beginning of period	105,301	12,867
Reconciliation of cash, cash equivalents, and restricted cash, end of period
Cash and cash equivalents	56,281	15,254
Restricted cash	5,003	5,001
Cash and cash equivalents, end of period	61,284	20,255
Supplemental disclosure for cash flow information:
Cash paid for interest, net of amounts capitalized	14,028	5,922
Cash paid for income taxes	156	8,360
Supplemental non-cash investing and financing activities:
Debt issuance costs in accrued expenses	0	81
Acquisition of product rights included in accounts payable	1,000	0
Property and equipment purchased and included in accounts payable	$ 204	$ 28

BUSINESS, PRESENTATION, AND REC

BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2022
BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS
BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS	1. BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS Overview ANI Pharmaceuticals, Inc. and its consolidated subsidiaries (together, “ANI,” the “Company,” “we,” “us,” or “our”) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals, including for diseases with high unmet medical need. Our team is focused on delivering growth by building a successful Purified Cortrophin Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our manufacturing capabilities. Our four pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, one is located in East Windsor, New Jersey, and one is located in Oakville, Ontario, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. On June 2, 2022, we announced that we intend to cease operations at our Oakville, Ontario, Canada manufacturing plant by first quarter 2023. This action is part of ongoing initiatives to capture operational synergies following our acquisition of Novitium Pharma LLC (“Novitium”) in November 2021. We are in the process of transitioning the majority of products manufactured or packaged in Oakville to one of our three U.S.-based manufacturing sites, and we are seeking to find potential buyers for the Oakville site. Our operations are subject to certain risks and uncertainties including, among others, current and potential competitors with greater resources, dependence on significant customers, and possible fluctuations in financial results. The accompanying unaudited interim condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations, and potential other funding sources, including cash on hand, to meet our obligations as they become due. We believe the going-concern basis is appropriate for the accompanying unaudited interim condensed consolidated financial statements based on our current operating plan and business strategy for the 12 months following the issuance of this report. As we continue to invest in our Rare Disease segment, we reported net losses of $8.6 million and $43.7 million for the three and nine months ended September 30, 2022, respectively, and the Accumulated Deficit as of September 30,2022 was $92.6 million. Despite those results, we believe that our financial resources, consisting of current working capital, anticipated future operating revenue and corresponding collections from customers, and our Credit Facility, under which $40.0 million remains available for borrowing as of September 30, 2022, will be sufficient to enable us to meet our working capital requirements and debt obligations for at least the next 12 months. Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain prior period information has been reclassified to conform to the current period presentation. In our opinion, the accompanying unaudited interim condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations, comprehensive income/(loss), and cash flows. The consolidated balance sheet at December 31, 2021 has been derived from audited financial statements as of that date. The unaudited interim condensed consolidated statements of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the U.S. Securities and Exchange Commission (the “SEC”). We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim condensed consolidated financial statements are read in conjunction with the audited financial statements and notes previously distributed in our Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Form 10-K”). Principles of Consolidation The unaudited interim condensed consolidated financial statements include the accounts of ANI Pharmaceuticals, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Foreign Currency We have subsidiaries located in Canada and India. The Canada-based subsidiary conducts its transactions in U.S. dollars and Canadian dollars, but its functional currency is the U.S. dollar. The Indian-based subsidiary generally conducts its transactions in Indian rupees, which is also its functional currency. The results of any non-U.S. dollar transactions and balances are remeasured in U.S. dollars at the applicable exchange rates during the period and resulting foreign currency transaction gains and losses are included in the determination of net income. Our gain or loss on transactions denominated in foreign currencies and the translation impact of local currencies to U.S. dollars was immaterial for the three and nine months ended September 30, 2022 and 2021. Unless otherwise noted, all references to “$” or “dollar” refer to the U.S. dollar. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the condensed consolidated financial statements, estimates are used for, but not limited to, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, income tax provision or benefit, deferred taxes and valuation allowance, stock-based compensation, revenue recognition, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, including contingent consideration in acquisitions, fair value of long-lived assets, determination of right-of-use assets and lease liabilities, allowance for credit losses, purchase price allocations, and the depreciable lives of long-lived assets. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness. Restructuring Activities We define restructuring activities to include costs directly associated with exit or disposal activities. Such costs include cash employee contractual severance and other termination benefits, one-time employee termination severance and benefits, contract termination charges, impairment and acceleration of depreciation associated with long-lived assets, and other exit or disposal costs. In general, we record involuntary employee- related exit and disposal costs when there is a substantive plan for employee severance and related payments are probable and estimable. For one-time termination benefits, including those with a service requirement, expense is recorded when the employees are entitled to receive such benefits and the amount can be reasonably estimated. Expense related to one-time termination benefits with a service requirement is recorded over time, as the service is completed. Contract termination fees and penalties, and other exit and disposal costs are generally recorded as incurred. Restructuring activities are recognized as an operating expense in our consolidated statement of operations. Recent Accounting Pronouncements Recent Accounting Pronouncements Not Yet Adopted We have evaluated all issued and unadopted Accounting Standards Updates and believe the adoption of these standards will not have a material impact on our condensed consolidated statements of operations, comprehensive income, balance sheets, or cash flows.

REVENUE RECOGNITION AND RELATED

REVENUE RECOGNITION AND RELATED ALLOWANCES	9 Months Ended
REVENUE RECOGNITION AND RELATED ALLOWANCES	Sep. 30, 2022
REVENUE RECOGNITION AND RELATED ALLOWANCES
REVENUE RECOGNITION AND RELATED ALLOWANCES	2. REVENUE RECOGNITION AND RELATED ALLOWANCES Revenue Recognition We recognize revenue using the following steps: ● Identification of the contract, or contracts, with a customer; ● Identification of the performance obligations in the contract; ● Determination of the transaction price, including the identification and estimation of variable consideration; ● Allocation of the transaction price to the performance obligations in the contract; and ● Recognition of revenue when we satisfy a performance obligation. We derive our revenues primarily from sales of generic and branded pharmaceutical products. Revenue is recognized when our obligations under the terms of our contracts with customers are satisfied, which generally occurs when control of the products we sell is transferred to the customer. We estimate variable consideration after considering applicable information that is reasonably available. We generally do not have incremental costs to obtain contracts that would otherwise not have been incurred. We do not adjust revenue for the promised amount of consideration for the effects of a significant financing component because our customers generally pay us within 100 days. All revenue recognized in the accompanying unaudited interim condensed consolidated statements of operations is considered to be revenue from contracts with customers. The following table depicts the disaggregation of revenue: Three Months Ended Nine Months Ended Products and Services September 30, September 30, September 30, September 30, (in thousands) 2022 2021 2022 2021 Sales of generic pharmaceutical products $ 53,136 $ 35,140 $ 152,106 $ 101,952 Sales of established brand pharmaceutical products 9,816 14,313 26,731 32,868 Sales of rare disease pharmaceutical products 12,602 — 24,096 — Sales of contract manufactured products 4,779 2,382 12,072 7,277 Royalties from licensing agreements 1,821 — 3,918 11,210 Product development services 1,503 77 2,600 332 Other 164 149 630 1,568 Total net revenues $ 83,821 $ 52,061 $ 222,153 $ 155,207 Three Months Ended Nine Months Ended Timing of Revenue Recognition September 30, September 30, September 30, September 30, (in thousands) 2022 2021 2022 2021 Performance obligations transferred at a point in time $ 82,318 $ 51,984 $ 219,553 $ 154,875 Performance obligations transferred over time 1,503 77 2,600 332 Total $ 83,821 $ 52,061 $ 222,153 $ 155,207 In the three and nine months ended September 30, 2022 and 2021, we did not incur, and therefore did not defer, any material incremental costs to obtain or fulfill contracts. We recognized a decrease of $2.6 million to net revenue from performance obligations satisfied in prior periods during the nine months ended September 30, 2022, consisting primarily of revised estimates for variable consideration, including chargebacks, rebates, returns, and other allowances, related to prior period sales. in Royalties from Licensing Agreements. For the three and nine months ended September 30, 2021, we recognized less than $0.1 million of revenue that was included in deferred revenue as of December 31, 2020. Revenue from Sales of Generic and Branded Pharmaceutical Products Product sales consists of sales of our generic and branded pharmaceutical products, including rare disease pharmaceutical products. Our sole performance obligation in our contracts is to provide pharmaceutical products to customers. Our products are sold at pre-determined standalone selling prices and our performance obligation is considered to be satisfied when control of the product is transferred to the customer. Control is generally transferred to the customer upon delivery of the product to the customer, as our pharmaceutical products are generally sold on an FOB destination basis and because inventory risk and risk of ownership passes to the customer upon delivery. Payment terms for these sales are generally less than 100 days. Sales of our pharmaceutical products are subject to variable consideration due to chargebacks, government rebates, returns, administrative and other rebates, and cash discounts. Estimates for these elements of variable consideration require significant judgment. The following table summarizes activity in the consolidated balance sheets for accruals and allowances for the nine months ended September 30, 2022 and 2021, respectively: Accruals for Chargebacks, Returns, and Other Allowances Administrative Prompt Government Fees and Other Payment (in thousands) Chargebacks Rebates Returns Rebates Discounts Balance at December 31, 2020 $ 88,746 $ 7,826 $ 27,155 $ 8,906 $ 3,839 Accruals/Adjustments 343,117 31,515 16,043 74,594 31,138 Credits Taken Against Reserve (333,867) (27,628) (10,969) (75,877) (30,876) Balance at September 30, 2021 (1) $ 97,996 $ 11,713 $ 32,229 $ 7,623 $ 4,101 Balance at December 31, 2021 $ 94,066 $ 5,492 $ 35,831 $ 13,100 $ 4,642 Accruals/Adjustments 480,626 14,104 18,751 30,475 15,746 Credits Taken Against Reserve (480,203) (10,851) (20,598) (28,766) (15,751) Balance at September 30, 2022 (1) $ 94,489 $ 8,745 $ 33,984 $ 14,809 $ 4,637 (1) Chargebacks are included as an offset to accounts receivable in the unaudited interim condensed consolidated balance sheets. Administrative Fees and Other Rebates and Prompt Payment Discounts are included as an offset to accounts receivable or as accrued expenses and other in the unaudited interim condensed consolidated balance sheets. Returns are included in returned goods reserve in the unaudited interim condensed consolidated balance sheets. Government Rebates are included in accrued government rebates in the unaudited interim condensed consolidated balance sheets. Contract Manufacturing Product Sales Revenue Contract manufacturing arrangements consist of agreements in which we manufacture a pharmaceutical product on behalf of a third party. Our performance obligation is to manufacture and provide pharmaceutical products to customers, typically pharmaceutical companies. The contract manufactured products are sold at pre-determined standalone selling prices and our performance obligations are considered to be satisfied when control of the product is transferred to the customer. Control is transferred to the customer when the product leaves our dock to be shipped to the customer, as our contract manufactured pharmaceutical products are sold on an FOB shipping point basis and the inventory risk and risk of ownership passes to the customer at that time. Payment terms for these sales are generally fewer than two months. We estimate returns based on historical experience. Historically, we have not had material returns for contract manufactured products. As of September 30, 2022, the aggregate amount of the transaction price allocated to the remaining performance obligations for all open contract manufacturing customer contracts was $7.5 million, which consists of firm orders for contract manufactured products. We will recognize revenue for these performance obligations as they are satisfied, which is anticipated within six months. Royalties from Licensing Agreements From time to time, we enter into transition agreements with the sellers of products we acquire, under which we license to the seller the right to sell the acquired products. Therefore, we recognize the revenue associated with sales of the underlying products as royalties. Because these royalties are sales-based, we recognize the revenue when the underlying sales occur, based on sales and gross profit information received from the sellers. Upon full transition of the products and upon launching the products under our own labels, we recognize revenue for the products as sales of generic or branded pharmaceutical products, as described above. From time to time, we enter into supply and distribution agreements with contract manufacturing customers, under which we license to the contract manufacturing customer the right to sell our products, and we are entitled to a royalty on sales made by the contract manufacturing customer under these arrangements. Therefore, we recognize the revenue associated with sales of the underlying products as royalties. Because these royalties are sales-based, we recognize the revenue when the underlying sales occur, based on sales and gross profit information received from the contract manufacturing customers. Pursuant to a 2012 Tripartite Agreement (the “Tripartite Agreement”) between the Company, The Regents of the University of California (“The Regents”), and Cabaret Biotech Ltd., an Israeli corporation (“Cabaret”) (as assignee of Dr. Zelig Eshhar’s rights under the Tripartite Agreement), and subsequent amendments thereto and assignments thereof, we were entitled to receive a percentage of the milestone and sales royalty payments paid to Cabaret by Kite Pharma, Inc. (“Kite”), a subsidiary of Gilead Sciences, Inc., under a license agreement. Under such license agreement, Kite licensed from Dr. Eshhar and Cabaret the patent rights covered by the Tripartite Agreement and agreed to make certain payments to Cabaret based on, among other things, Kite’s sales of Yescarta®. Under the Tripartite Agreement, portions of these payments were to be distributed to The Regents and to us. Historically, we recorded royalty income related to Yescarta® on an accrual basis utilizing our best estimate of royalties earned based upon information available in the public domain, our understanding of the various agreements governing the royalty, and other information received from time to time from the relevant parties. Generally, cash was received directly from Cabaret once a year. The agreements governing this royalty were subject to multiple actions in multiple jurisdictions, including litigation between Cabaret and Kite, and separately, ANI and Cabaret. In the first quarter of 2021, we became aware that the litigation between Cabaret and Kite was dismissed. In April 2021, Cabaret and the Company settled all amounts due for amounts actually received by Cabaret or Eshhar for the licensing or use of the patent rights governed by the Kite license agreement. As a result, we recognized million, which has been recorded as other expense, net in the accompanying unaudited interim condensed consolidated statement of operations, related to certain legal expenditures incurred. We received final payment from Cabaret in May 2021. Based upon the events that led to the dismissal of the litigation between Cabaret and Kite, we do not expect to receive any future royalty income related to the Kite license agreement. In conjunction with payment of amounts due to us, all outstanding litigation between the Company and Cabaret was dismissed. Product Development Services Revenue We provide product development services to customers, which are performed over time. These are services primarily performed at our facilities in East Windsor, New Jersey and Oakville, Ontario. As we intend to cease operations at the Oakville, Ontario facility by the first quarter of 2023, we are in the process of transitioning the product development services at the facility to one of our three U.S.-based manufacturing sites. The duration of these development projects can be up to three years. Deposits received from these customers are recorded as deferred revenue until revenue is recognized. For contracts with no deposits and for the remainder of contracts with deposits, we invoice customers as our performance obligations are satisfied. We recognize revenue on a percentage of completion basis, which results in contract assets on our balance sheet. As of September 30, 2022, the aggregate amount of the transaction price allocated to the remaining performance obligations for all open product development services contracts was $0.2 million. We expect to satisfy these performance obligations within the next six months. Credit Concentration Our customers are primarily wholesale distributors, chain drug stores, group purchasing organizations, and pharmaceutical companies. During the three and nine months ended September 30, 2022 and 2021 we had three customers that accounted for 10% or more of net revenues. As of September 30, 2022, accounts receivable from these customers totaled 80% of accounts receivable, net. The three customers represent the total percentage of net revenues as follows: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 Customer 1 23 % 31 % 26 % 29 % Customer 2 17 % 23 % 18 % 22 % Customer 3 16 % 17 % 15 % 15 %

BUSINESS COMBINATION

BUSINESS COMBINATION	9 Months Ended
BUSINESS COMBINATION	Sep. 30, 2022
BUSINESS COMBINATION
BUSINESS COMBINATION	3. BUSINESS COMBINATION Summary On November 19, 2021, we completed our previously announced acquisition of all of the interests of Novitium pursuant to the terms of the Agreement and Plan of Merger (the “Merger Agreement”), dated as of March 8, 2021, for cash consideration, 2,466,654 restricted shares of our common stock valued at $91.2 million based on our closing stock price of $43.54 on the date of closing and discounted for lack of marketability due to restrictions on shares, and up to $46.5 million in additional contingent consideration. Additionally, we agreed to pay certain debts of Novitium in the amount of $8.5 million, which we deemed to be paid in consummation of the transaction closing, and not assumed liabilities, and thus were included as additional cash consideration. This acquisition was accounted for as a business combination. The contingent consideration is based on the achievement of certain milestones, including milestones on gross profit of Novitium portfolio products over a 24-month 24-month Refer to Note 14 for changes in contingent consideration and changes in fair value. Purchase consideration consisted of the following: (in thousands) Cash consideration $ 88,109 Repayment of Novitium debts 8,493 Fair value of restricted shares 91,199 Fair value of contingent consideration 30,800 Gross consideration $ 218,601 Cash acquired 12,076 Net consideration $ 206,525 The cash consideration was funded in part by borrowings under our new credit facility (Note 5) and through issuance of shares of Series A convertible preferred stock (Note 10). We acquired Novitium due to its proven track record of being a research and development growth engine capable of fueling growth, to expand our research and development pipeline via niche opportunities, to enhance our contract development and manufacturing organization (“CDMO”) business and U.S.-based manufacturing capacity, and to diversify our revenue base. The following presents the final allocation of the purchase price to the assets acquired and liabilities assumed on November 19, 2021: (in thousands) Total Purchase Consideration $ 218,601 Cash and cash equivalents 12,076 Accounts receivable 27,185 Inventories 14,460 Prepaid expenses and other current assets 1,891 Property and equipment 14,331 Intangible assets 139,200 Goodwill 24,641 Other non-current assets 1,413 Total assets acquired 235,197 Accounts payable 1,560 Accrued expense and other current liabilities 6,035 Accrued compensation and other related expenses 4,909 Accrued government rebates 744 Returned goods reserve 2,202 Other non-current liabilities 1,146 Total liabilities assumed 16,596 Net assets acquired $ 218,601 The net assets were recorded at their estimated fair value. In valuing acquired assets and liabilities, fair value estimates were based primarily on future expected cash flows, market rate assumptions for contractual obligations, and appropriate discount rates. In connection with the acquisition, we recognized $46.9 million of indefinite-lived in-process research and development intangible assets, $67.4 million of acquired ANDA intangible assets, and $24.9 million of customer relationship intangible assets. Goodwill is considered an indefinite-lived asset and relates primarily to intangible assets that do not qualify for separate recognition, such as the assembled workforce and synergies between the entities. Goodwill established as a result of the acquisition is tax deductible in the U.S. Novitium operations generated $24.0 million and $63.1 million of revenue during the three and nine months ended September 30, 2022, respectively. Restricted Shares The Novitium acquisition consideration included 2,466,654 restricted shares, which were valued at $91.2 million. These shares contain restrictions on their transfer for periods from three

RESTRUCTURING

RESTRUCTURING	9 Months Ended
RESTRUCTURING	Sep. 30, 2022
RESTRUCTURING
RESTRUCTURING	4. RESTRUCTURING On June 2, 2022, we announced that we intend to cease operations at our Oakville, Ontario, Canada manufacturing plant by the first quarter of 2023. This action is part of ongoing initiatives to capture operational synergies following our acquisition of Novitium in November 2021. We are in the process of transitioning the majority of products manufactured or packaged in Oakville to one of our three U.S.-based manufacturing sites. We are seeking to find potential buyers for the Oakville site, though there can be no assurance as to when or if that will occur or the amount of any net proceeds that may be received. For the three and nine months ended September 30, 2022, restructuring activities resulted in expenses of $1.5 million and $4.1 million, respectively. This included $0.4 million and $1.8 million of severance and other employee benefit costs and $1.2 million and $2.1 million of asset-related impairment and accelerated depreciation costs, for the three and nine months ended September 30, 2022, respectively. There were also $0.3 million of other costs year to date, all recorded in the quarter ended June 30, 2022. As of September 30, 2022, $1.1 million of the severance and other employee benefits are unpaid and accrued. These costs are recorded as restructuring activities, an operating item, in the accompanying unaudited interim condensed consolidated statements of operations. Certain of the severance and other employee benefit costs contain a service requirement, and as such, are being accrued over time as they are earned. We expect to incur additional charges of approximately $0.6 million in these costs over the next six months, and approximately $1.9 million to $2.4 million future asset-related accelerated depreciation charges over this period. These costs are part of the Generics, Established Brands, and Other segment. In conjunction with the planned exit of our Canadian facility, we have determined that the land and building at our Oakville, Ontario, Canada plant will be sold together over the transition period and meet the criteria to be classified as held for sale as of September 30, 2022. The land and building have a net carrying value of $8.0 million, which is presented as assets held for sale

INDEBTEDNESS

INDEBTEDNESS	9 Months Ended
INDEBTEDNESS	Sep. 30, 2022
INDEBTEDNESS
INDEBTEDNESS	5. INDEBTEDNESS Credit Facility On November 19, 2021, the Company, as borrower, entered into a credit agreement (the “Credit Agreement”) with Truist Bank and other lenders, which provides for credit facilities consisting of (i) a senior secured term loan facility in an aggregate principal amount of $300.0 million (the “Term Facility”) and (ii) a senior secured revolving credit facility in an aggregate commitment amount of $40.0 million, which may be used for revolving credit loans, swingline loans and letters of credit (the “Revolving Facility,” and together with the Term Facility, the “Credit Facility”). The Term Facility proceeds were used to finance the cash portion of the consideration under the Merger Agreement, repay our existing credit facility, and pay fees, costs and expenses incurred in connection with the merger. Proceeds from the Revolving Facility are expected to be used, subject to certain limitations, for working capital and other general corporate purposes. The Term Facility matures in November 2027 and the Revolving Facility in November 2026. Each permits both base rate borrowings (“ABR Loans”) and Eurodollar rate borrowings (“Eurodollar Loans”), plus a spread of (a) 5.00% above the base rate in the case of ABR Loans under the Term Facility and 6.00% above the LIBOR Rate (as defined in the Credit Agreement) in the case of LIBOR loans under the Term Facility and (b) 3.75% above the base rate in the case of ABR Loans under the Revolving Facility and 4.75% above the LIBOR Rate (as defined in the Credit Agreement) in the case of loans under the Revolving Facility. The interest rate under the Term Facility was 9.14% at September 30, 2022. The Credit Facility has a subjective acceleration clause in case of a material adverse effect. The Term Facility includes a repayment schedule, pursuant to which $750 thousand of the loan will be paid in quarterly installments during the twelve months ended September 30, 2023. As of September 30, 2022, $3.0 million of the loan is recorded as current borrowings in the unaudited interim condensed consolidated balance sheets. As of September 30, 2022, we had not drawn on the Revolving Facility and $40.0 million remained available for borrowing subject to certain conditions. We incurred $14.0 million in deferred debt issuance costs associated with the Credit Facility. Costs allocated to the Term Facility are classified as a direct reduction to the current and non-current portion of the borrowings, depending on their nature. Costs allocated to the Revolving Facility are classified as other current and other non-current assets, depending on their nature. We incur a commitment fee of 0.5% per annum on any unused portion of the Revolving Facility. In connection with entry into the Credit Facility, on November 19, 2021, we terminated our existing Amended and Restated Credit Agreement, dated as of December 27, 2018 (the “Prior Credit Agreement”), among the Company, as borrower, and Citizens Bank with other lenders. The Credit Facility is secured by a lien on substantially all of ANI Pharmaceuticals, Inc.’s and its principal domestic subsidiary’s assets and any future domestic subsidiary guarantors’ assets. The Credit Facility is subject to customary financial and nonfinancial covenants. The carrying value of the current and non-current components of the Term Facility as of September 30, 2022 and December 31, 2021 are: Current September 30, December 31, (in thousands) 2022 2021 Current borrowing on debt $ 3,000 $ 3,000 Deferred financing costs (2,150) (2,150) Current debt, net of deferred financing costs $ 850 $ 850 Non-Current September 30, December 31, (in thousands) 2022 2021 Non-current borrowing on debt $ 294,750 $ 297,000 Deferred financing costs (8,868) (10,480) Non-current debt, net of deferred financing costs and current component $ 285,882 $ 286,520 As of September 30, 2022, we had a $297.8 million balance on the Term Facility. Of the $0.9 million of unamortized deferred debt issuance costs allocated to the Revolving Facility, $0.7 million is included in other non-current assets in the unaudited interim condensed consolidated balance sheets, and $0.2 million is included in prepaid expenses and other current assets in the unaudited interim condensed consolidated balance sheets. The contractual maturity of our Term Facility is as follows for the years ending December 31: (in thousands) Term Facility 2022 $ 750 2023 3,000 2024 3,000 2025 3,000 2026 3,000 2027 and thereafter 285,000 Total $ 297,750 The following table sets forth the components of total interest expense related to the Term Facility during the three and nine months ended September 30, 2022 and interest expense under the Prior Credit Agreement during the three and nine months ended September 30, 2021, as recognized in the accompanying unaudited interim condensed consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, (in thousands) 2022 2021 2022 2021 Contractual coupon $ 6,834 $ 2,342 $ 19,014 $ 7,032 Amortization of finance fees 592 175 1,773 527 Capitalized interest (31) (17) (80) (74) $ 7,395 $ 2,500 $ 20,707 $ 7,485

DERIVATIVE FINANCIAL INSTRUMENT

DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY	9 Months Ended
DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY	Sep. 30, 2022
DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY
DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY	6. DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY At times we use derivative financial instruments to hedge our exposure to interest rate risks. All derivative financial instruments are recognized as either assets or liabilities at fair value on the consolidated balance sheet and are classified as current or non-current based on the scheduled maturity of the instrument. When we enter into a hedge arrangement and intend to apply hedge accounting, we formally document the hedge relationship and designate the instrument for financial reporting purposes as a fair value hedge, a cash flow hedge, or a net investment hedge. When we determine that a derivative financial instrument qualifies as a cash flow hedge and is effective, the changes in fair value of the instrument are recorded in accumulated other comprehensive loss, net of tax in our consolidated balance sheets and will be reclassified to earnings when the hedged item affects earnings. In April 2020, we entered into an interest rate swap with Citizens Bank, N.A. to manage our exposure to changes in LIBOR-based interest rates underlying total borrowings under term facilities related to our Prior Credit Agreement. The interest rate swap matures in December 2026. Concurrent with the termination of the Prior Credit Agreement and entry into the Credit Agreement with Truist Bank, the interest rate swap with a notional value of $168.6 million was novated and Truist Bank is the new counterparty. The swap is used to manage changes in LIBOR-based interest rates underlying a portion of the borrowing under the Term Facility. The interest rate swap provides an effective fixed interest rate of 2.26% and has been designated as an effective cash flow hedge and therefore qualifies for hedge accounting. As of September 30, 2022, the notional amount of the interest rate swap was $155.1 million and decreases quarterly by approximately $4.0 million until December 2023, after which it remains static until maturity in December 2026. As of September 30, 2022, the fair value of the interest rate swap asset recorded in derivatives and other non-current assets in the unaudited interim condensed consolidated balance sheets was $9.4 million. As of September 30, 2022, $10.0 million was recorded in accumulated other comprehensive loss, net of tax in the unaudited interim condensed consolidated balance sheets. During the three and nine months ended September 30, 2022, the change in fair value of the interest rate swaps was a gain of $5.4 million and $15.3 million, respectively. During the three and nine months ended September 30, 2022, gains on the interest rate swap of $4.6 million and $13.1 million were recorded in accumulated other comprehensive loss, net of tax in our unaudited interim condensed consolidated statements of comprehensive (loss)/income, respectively. Differences between the hedged LIBOR rate and the fixed rate are recorded as interest expense in the same period that the related interest is recorded for the Term Facility based on the LIBOR rate. In the three and nine months ended September 30, 2022, $0.4 million and $2.4 million of interest expense was recognized in relation to the interest rate swaps, respectively. Included in this amount for the three months ended September 30, 2022 and 2021 are reclassifications out of accumulated other comprehensive income/loss of $0.7 million and $1.7 million and during the nine months ended September 30, 2022 and 2021 are $2.1 million and $5.5 million in expense, respectively, related to terminated and de-designated cash flow hedges.

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	9 Months Ended
EARNINGS (LOSS) PER SHARE	Sep. 30, 2022
EARNINGS (LOSS) PER SHARE
EARNINGS (LOSS) PER SHARE	7. EARNINGS (LOSS) PER SHARE Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings (loss) per share by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options, shares to be purchased under our Employee Stock Purchase Plan (“ESPP”), unvested restricted stock awards, and stock purchase warrants, using the treasury stock method. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share. Our unvested restricted shares and Series A convertible preferred stock shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; in periods of net income, the calculation of basic and diluted earnings (loss) per share excludes from the numerator net income (but not net loss) attributable to the unvested restricted shares and the common shares assumed converted from the preferred shares and excludes the impact of those shares from the denominator. Earnings (loss) per share for the three and nine months ended September 30, 2022 and 2021 are calculated for basic and diluted earnings (loss) per share as follows: Basic Diluted Basic Diluted (in thousands, except per share amounts) Three Months Ended September 30, Three Months Ended September 30, Nine Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 2022 2021 2022 2021 Net loss $ (8,600) $ (4,447) $ (8,600) $ (4,447) $ (43,653) $ (18,467) $ (43,653) $ (18,467) Net income allocated to participating securities — — — — — — — — Dividends on Series A convertible preferred stock (406) — (406) — (1,218) — (1,218) — Net loss available to common shareholders $ (9,006) $ (4,447) $ (9,006) $ (4,447) $ (44,871) $ (18,467) $ (44,871) $ (18,467) Basic Weighted-Average Shares Outstanding 16,303 12,107 16,303 12,107 16,238 12,066 16,238 12,066 Dilutive effect of stock options and ESPP — — — — Diluted Weighted-Average Shares Outstanding 16,303 12,107 16,238 12,066 Loss per share $ (0.55) $ (0.37) $ (0.55) $ (0.37) $ (2.76) $ (1.53) $ (2.76) $ (1.53) The number of anti-dilutive shares, which have been excluded from the computation of diluted earnings (loss) per share, was 2.7 million and 1.6 million for the three months ended September 30, 2022 and 2021 and was 2.7 million and 1.7 million for the nine months ended September 30, 2022 and 2021, respectively. For the three and nine months ended September 30, 2022 and 2021, all potentially dilutive shares were anti-dilutive and excluded from the calculation of diluted loss per share because we recognized a net loss.

INVENTORIES

INVENTORIES	9 Months Ended
INVENTORIES	Sep. 30, 2022
INVENTORIES
INVENTORIES	8. INVENTORIES Inventories consist of the following as of: September 30, December 31, (in thousands) 2022 2021 Raw materials $ 62,423 $ 51,350 Packaging materials 7,871 5,475 Work-in-progress 1,097 652 Finished goods 33,936 31,969 105,327 89,446 Reserve for excess/obsolete inventories (9,434) (7,753) Inventories, net $ 95,893 $ 81,693 Vendor Concentration We source the raw materials for our products, including active pharmaceutical ingredients (“API”), from both domestic and international suppliers. Generally, only a single source of API is qualified for use in each product due to the cost and time required to validate a second source of supply. As a result, we are dependent upon our current vendors to reliably supply the API required for on-going product manufacturing. During the three months ended September 30, 2022, no single vendor represented more than 10% of inventory purchases. During the nine months ended September 30, 2022, we purchased approximately 13% of our inventory from one supplier. As of September 30, 2022, there was no amount payable to this supplier. During the three and nine months ended September 30, 2021, no single vendor represented more than 10% of inventory purchases.

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	9 Months Ended
GOODWILL AND INTANGIBLE ASSETS	Sep. 30, 2022
GOODWILL AND INTANGIBLE ASSETS
GOODWILL AND INTANGIBLE ASSETS	9. GOODWILL AND INTANGIBLE ASSETS Goodwill As a result of our 2013 merger with BioSante Pharmaceuticals, Inc. (“BioSante”), we recorded goodwill of $1.8 million. As a result of our acquisition of WellSpring Pharma Services Inc., we recorded additional goodwill of $1.7 million in 2018. From our acquisition of Novitium in 2021, we recorded goodwill of $24.6 million. We assess the recoverability of the carrying value of goodwill as of October 31 st Intangible Assets The components of net definite-lived intangible assets and net indefinite-lived intangible assets other than goodwill are as follows: September 30, 2022 December 31, 2021 Weighted Average Gross Carrying Accumulated Gross Carrying Accumulated Amortization (in thousands) Amount Amortization Amount Amortization Period Definite-Lived Intangible Assets: Acquired ANDA intangible assets $ 189,087 $ (69,824) $ 168,536 $ (54,079) 8.3 years NDAs and product rights 242,372 (156,520) 242,372 (138,835) 9.9 years Marketing and distribution rights 17,157 (13,069) 17,157 (12,347) 5.5 years Non-compete agreement 624 (579) 624 (513) 7.0 years Customer relationships 24,900 (3,261) 24,900 (593) 7.0 years Indefinite-Lived Intangible Assets: In process research and development 33,350 — 46,900 — Indefinite Total Intangible Assets, net $ 507,490 $ (243,253) $ 500,489 $ (206,367) 8.9 years The definite-lived Abbreviated New Drug Applications (“ANDAs”), New Drug Applications (“NDAs”) and product rights, marketing and distribution rights, customer relationships, and non-compete agreement are stated at cost, net of amortization, and generally amortized over their remaining estimated useful lives, ranging from seven ANDA Amortization expense was $12.5 million and $10.1 million for the three months ended September 30, 2022 and 2021, respectively. Amortization expense was $36.9 million and $29.8 million for the nine months ended September 30, 2022 and 2021, respectively. We test for impairment of definite-lived intangible assets and indefinite-lived intangible assets when events or circumstances indicate that the carrying value of the assets may not be recoverable. No such triggering events were identified in the three months ended September 30, 2022. In the nine months ended September 30, 2022, we recognized a full impairment of a definite-lived ANDA asset with a remaining carrying value of $0.1 million. No such triggering events were identified during the three and nine months ended September 30, 2021 and therefore no impairment loss was recognized in the three and nine months ended September 30, 2021. Expected future amortization expense is as follows: (in thousands) 2022 (remainder of the year) $ 12,602 2023 51,792 2024 50,996 2025 48,893 2026 35,574 2027 and thereafter 64,380 Total $ 264,237 Expected amortization expense is an estimate. Actual amounts of amortization expense may differ due to timing of regulatory approvals related to IPR&D assets, additional intangible assets acquired, impairment of intangible assets, and other events.

MEZZANINE AND STOCKHOLDERS' EQU

MEZZANINE AND STOCKHOLDERS' EQUITY	9 Months Ended
MEZZANINE AND STOCKHOLDERS' EQUITY	Sep. 30, 2022
MEZZANINE AND STOCKHOLDERS' EQUITY
MEZZANINE AND STOCKHOLDERS' EQUITY	10. MEZZANINE AND STOCKHOLDERS’ EQUITY Stockholders’ Equity Authorized shares We are authorized to issue up to 33.3 million shares of common stock with a par value of $0.0001 per share, 0.8 million shares of class C special stock with a par value of $0.0001 per share, and 1.7 million shares of undesignated preferred stock with a par value of $0.0001 per share at September 30, 2022. There were 17.6 million and 17.5 million shares of common stock issued and outstanding as of September 30, 2022, respectively, and 16.9 million and 16.8 million shares of common stock issued and outstanding as of December 31, 2021, respectively. During 2021, we issued 1.5 million shares related to a public offering of our common stock and 2.5 million shares as consideration in connection with the acquisition of Novitium. There were 11 thousand shares of class C special stock issued and outstanding Mezzanine Equity PIPE Shares Concurrently with the execution of the Merger Agreement, and as financing for a portion of the acquisition, on March 8, 2021, we entered into an Equity Commitment and Investment Agreement with Ampersand 2020 Limited Partnership (the “PIPE Investor”), pursuant to which we agreed to issue and sell to the PIPE Investor, and the PIPE Investor agreed to purchase, 25,000 shares of our Series A Convertible Preferred Stock (the “PIPE Shares”), for a purchase price of $1,000 per share and an aggregate purchase price of $25.0 million. This agreement closed and the 25,000 PIPE Shares were sold and issued for $25.0 million on November 19, 2021. The PIPE Shares are classified as mezzanine equity because the shares are mandatorily redeemable for cash upon a change in control, an event that is not solely in our control. We incurred $0.2 million in issuance costs associated with the transaction. The PIPE Shares accrue dividends at 6.50% per year on a cumulative basis, payable in cash or in-kind, and will also participate, on a pro-rata basis, in any dividends that may be declared with respect to our common stock. The PIPE Shares are convertible into our common shares at the conversion price of $41.47 (i) beginning two years after their issuance date, at the election of ANI (in which case the PIPE Investor must convert all of the PIPE Shares), if the volume-weighted average price of our common stock for any 20 trading days out of 30 consecutive trading days exceeds 170% of the conversion price, and (ii) at any time after issuance, at the election of the PIPE Investor. As of September 30, 2022, the PIPE shares are currently convertible into a maximum of 602,901 shares of our common stock. In case of a liquidation event, the holder of the PIPE Shares will be entitled to receive, in preference to holders of our common stock, the greater of (i) the PIPE Shares’ purchase price plus any accrued and unpaid dividends thereon and (ii) the amount the holder of the PIPE Shares would have received in the liquidation event if it had converted its PIPE Shares into our common stock. The PIPE Shares will have voting rights, voting as one series with our common stock, on as-converted basis, and will have separate voting rights on any (i) amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “Certificate”) that adversely amends and relates solely to the terms of the PIPE Shares and (ii) issuance of additional Series A convertible preferred stock. In case of a change of control of ANI, the PIPE Shares will be redeemed at the greater of (i) the PIPE Shares’ purchase price plus any accrued and unpaid dividends thereon and (ii) the change of control transaction consideration that the holder of the PIPE Shares would have received if it had converted into our common stock. There were 25,000 shares of Series A convertible preferred stock outstanding as of September 30, 2022.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
STOCK-BASED COMPENSATION	Sep. 30, 2022
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION	11. STOCK-BASED COMPENSATION Employee Stock Purchase Plan In July 2016, we commenced administration of the ANI Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan. As of September 30, 2022, we had 0.2 million shares of common stock available under the ESPP. Under the ESPP, participants can purchase shares of our stock at a 15% discount. The following table summarizes ESPP expense incurred under the 2016 Employee Stock Purchase Plan and included in our accompanying unaudited interim condensed consolidated statements of operations: (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cost of sales $ 11 $ 3 $ 40 $ 11 Research and development 10 5 31 16 Selling, general, and administrative 82 20 142 66 $ 103 $ 28 $ 213 $ 93 Stock Incentive Plan Equity-based service awards are granted under the ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan (the “2022 Plan”), which was approved by our stockholders at the 2022 Annual Meeting of Stockholders (the “Annual Meeting”) held on April 27, 2022. Prior to this approval, we had been granting equity-based incentive awards under our Sixth Amended and Restated 2008 Stock Incentive Plan (the “Existing Plan”). The 2022 Plan was amended to, among other things, increase the number of shares reserved for issuance thereunder by 1,150,000 shares. As of September 30, 2022, 1.0 million shares of our common stock were available for issuance under the Existing Plan. From time to time, we may grant stock options to employees through an inducement grant outside of our 2022 Plan to induce prospective employees to accept employment with us (the “Inducement Grants”). The options are granted at an exercise price equal to the fair market value of a share of our common stock on the respective grant date and are generally exercisable in four equal annual installments beginning on the first anniversary of the respective grant date. The grants are made pursuant to inducement grants outside of our stockholder approved equity plan as permitted under the Nasdaq Stock Market listing rules. The following table summarizes stock-based compensation expense incurred under the 2022 Plan and Inducement Grants included in our accompanying unaudited interim condensed consolidated statements of operations: (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cost of sales $ 134 $ 2 $ 393 $ 4 Research and development 186 144 531 407 Selling, general, and administrative 3,447 2,634 9,725 7,017 $ 3,767 $ 2,780 $ 10,649 $ 7,428 A summary of stock option and restricted stock activity under the 2022 Plan and Inducement Grants during the nine months ended September 30, 2022 and 2021 is presented below: (in thousands) Options Inducement Grants RSAs Outstanding at December 31, 2020 756 180 352 Granted 97 61 463 Options Exercised/RSAs Vested (5) — (126) (1) Forfeited (74) — (61) Expired — — — Outstanding at September 30, 2021 774 241 628 Outstanding at December 31, 2021 747 241 707 Granted 36 — 723 Options Exercised/RSAs Vested (16) — (234) (2) Forfeited (58) — (46) Expired — — — Outstanding at September 30, 2022 709 241 1,150 (1) Includes 28 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $0.9 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets. (2) Includes 63 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $1.9 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets .

INCOME TAXES

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 30, 2022
INCOME TAXES
INCOME TAXES	12. INCOME TAXES We use the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. As of September 30, 2022, we had provided a valuation allowance against consolidated net deferred tax assets of $0.4 million, related solely to deferred tax assets for net operating loss carryforwards in certain U.S. state jurisdictions. We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We have not identified any uncertain income tax positions that could have a material impact on the consolidated financial statements. We recognize interest and penalties accrued on any unrecognized tax exposures as a component of income tax expense; we did not have any such amounts accrued as of September 30, 2022 and December 31, 2021. We are subject to taxation in various U.S. jurisdictions, Canada, and India and all of our income tax returns remain subject to examination by tax authorities due to the availability of NOL carryforwards. For interim periods, we recognize an income tax provision/(benefit) based on our estimated annual effective tax rate, calculated on a worldwide consolidated basis, expected for the entire year. The interim annual estimated effective tax rate is based on the statutory tax rates then in effect, as adjusted for estimated changes in temporary and estimated permanent differences, and excludes certain discrete items whose tax effect, when material, is recognized in the interim period in which they occur. These changes in temporary differences, permanent differences, and discrete items result in variances to the effective tax rate from period to period. We also have elected to exclude the impacts from significant pre-tax non-recognized subsequent events from our interim estimated annual effective rate until the period in which they occur. Our estimated annual effective tax rate changes throughout the year as our on-going estimates of pre-tax income, changes in temporary differences, and permanent differences are revised, and as discrete items occur. Global Intangible Low-Taxed Income (“GILTI”), as defined in the Tax Cuts and Jobs Act of 2017, generated from our Canadian and Indian operations is subject to U.S. taxes, with certain defined exemptions, thresholds and credits. For financial reporting purposes we have elected to treat GILTI inclusions as a period cost. For the three months ended September 30, 2022, we recognized an income tax benefit of $3.6 million. The income tax benefit resulted from applying an estimated annual worldwide effective tax benefit rate of 29.6% to pre-tax consolidated loss of $12.2 million reported during the period, as well as the net effects of certain discrete items occurring which impact our income tax provision in the period in which they occur. There were no material discrete items occurring during the three months ended September 30, 2022. For the three months ended September 30, 2021, we recognized an income tax benefit of $2.7 million. The income tax benefit resulted from applying an estimated annual worldwide effective tax benefit rate of 37.6% to pre-tax consolidated loss of $7.1 million reported during the period, as well as the net effects of certain discrete items occurring which impact our income tax provision in the period in which they occur. There were no material discrete items occurring during the three months ended September 30, 2021. For the nine months ended September 30, 2022, we recognized an income tax benefit of $13.3 million. The income tax benefit resulted from applying an estimated annual worldwide effective tax benefit rate of 23.3% to pre-tax consolidated loss of $56.9 million reported during the period, as well as the net effects of certain discrete items occurring which impact our income tax provision in the period in which they occur. There were no material discrete items occurring during the nine months ended September 30, 2022. For the nine months ended September 30, 2021, we recognized an income tax benefit of $6.7 million. The income tax benefit resulted from applying an estimated annual worldwide effective tax benefit rate of 26.7% to pre-tax consolidated loss of $25.2 million reported during the period, as well as the net effects of certain discrete items occurring which impact our income tax provision in the period in which they occur. There were no material discrete items occurring during the nine months ended September 30, 2021. We expect that recent tax law changes contained in Inflation Reduction Act and the Creating Helpful Incentives to Produce Semiconductors and Science Act of 2022 (“CHIPS Act”) will not have a material impact on the provision for income taxes.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2022
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	13. COMMITMENTS AND CONTINGENCIES Operating Leases All our existing leases as of September 30, 2022 are classified as operating leases. As of September 30, 2022, we had 14 material operating leases for facilities and office equipment with remaining terms expiring from 2022 through 2027 and a weighted average remaining lease term of 2.8 years. Many of our existing leases have fair value renewal options, none of which are considered certain of being exercised or included in the minimum lease term. Discount rates used in the calculation of our lease liability ranged between 3.99% and 8.95%. Current lease liability is included in accrued expenses and other in the accompanying unaudited interim condensed consolidated balance sheets. Non-current lease liability is included in derivatives and other non-current liabilities in the accompanying unaudited interim condensed consolidated balance sheets. Rent expense for the three and nine months ended September 30, 2022 and 2021 consisted of the following: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2022 2021 2022 2021 Operating lease costs $ 201 $ 40 $ 470 $ 132 Variable lease costs 53 9 173 30 Total lease costs $ 254 $ 49 $ 643 $ 162 A maturity analysis of our operating leases follows: (in thousands) Future payments: 2022 $ 175 2023 761 2024 831 2025 431 2026 and thereafter 124 Total $ 2,322 Discount (237) Lease liability 2,085 Current lease liability (604) Non-current lease liability $ 1,481 Government Regulation Our products and facilities are subject to regulation by a number of federal and state governmental agencies, such as the Drug Enforcement Administration (“DEA”), the Food and Drug Administration (“FDA”), the Centers for Medicare and Medicaid Services (“CMS”), Health Canada, the Central Drugs Standard Control Organization (“CDSCO”), The Narcotics Control Bureau (“NCB”), and India’s Ministry of Health and Family Welfare (“MoHFW”). The FDA, in particular, maintains oversight of the formulation, manufacture, distribution, packaging, and labeling of all of our products. The DEA, Health Canada, and NCB maintain oversight over our products that are considered controlled substances. Unapproved Products Two of our products, Esterified Estrogen with Methyltestosterone (“EEMT”) and Opium Tincture, are marketed without approved NDAs or ANDAs. During the three months ended September 30, 2022 and 2021, net revenues for these products totaled $3.1 million and $4.2 million, respectively. During the nine months ended September 30, 2022 and 2021, net revenues for these products totaled $10.0 million and $12.2 million, respectively. In addition, one group of products that we manufacture on behalf of a contract customer is marketed by that customer without an approved NDA. If the FDA took enforcement action against such customer, the customer may be required to seek FDA approval for the group of products or withdraw them from the market. Our contract manufacturing revenues for the group of unapproved products for the three months ended September 30, 2022 and 2021 were $1.0 million and $0.7 million, respectively. Our contract manufacturing revenues for the group of unapproved products for the nine months ended September 30, 2022 and 2021 were $2.1 million. Legal proceedings We are involved, and from time to time may become involved, in various disputes, governmental and/or regulatory inquiries, investigations, government reimbursement related actions and litigation. These matters are complex and subject to significant uncertainties. Due to the inherent unpredictability of legal matters, including litigation, governmental and regulatory matters, particularly where the damages sought are substantial or indeterminate or when the proceedings, investigations or inquiries are in the early stages, we cannot accurately predict the outcome, or the effects of the legal proceedings described below. While we believe that we have valid claims and/or defenses in the litigation and other matters described below, litigation is inherently unpredictable, and the outcome of the proceedings could result in losses, including substantial damages, fines, civil or criminal penalties and injunctive or administrative remedies. We intend to vigorously prosecute and/or defend these matters, as appropriate; however, from time to time, we may settle or otherwise resolve these matters on terms and conditions that we believe are in our best interests. Resolution of any or all claims, investigations, and legal proceedings, individually or in the aggregate, could have a material adverse effect on our results of operations and/or cash flows in any given accounting period or on our overall financial condition. Some of these matters with which we are involved are described below and in our 2021 Form 10-K, and unless otherwise disclosed, we are unable to predict the outcome of the matter or to provide an estimate of the range of reasonably possible material losses. We record accruals for loss contingencies to the extent we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. From time to time, we are also involved in other pending proceedings for which, in our opinion based upon facts and circumstances known at the time, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to our results, and therefore remain undisclosed. If and when any reasonably possible losses associated with the resolution of such other pending proceedings, in our opinion, become material, we will disclose such matters. Furthermore, like many pharmaceutical manufacturers, we are periodically exposed to product liability claims. The prevalence of these claims could limit our coverage under future insurance policies or cause those policies to become more expensive, which could harm our business, financial condition, and operating results. Recent trends in the product liability and director and officer insurance markets is to exclude matters related to certain classes of drugs. Our policies have been subject to such exclusions which place further potential risk of financial loss on us. Legal fees for litigation-related matters are expensed as incurred and included in the condensed consolidated statements of operations under the selling, general, and administrative expense line item. Commercial Litigation In November of 2017, we were served with a complaint filed by Arbor Pharmaceuticals, LLC, in the United States District Court for the District of Minnesota. The complaint alleged false advertising and unfair competition in violation of Section 43(a) of the Lanham Act, Section 1125(a) of Title 15 of the United States Code, and Minnesota State law, under the premise that we sold an unapproved Erythromycin Ethylsuccinate (“EES”) product during the period between September 27, 2016 and November 2, 2018. The complaint sought a trial by jury and monetary damages (inclusive of actual and consequential damages, treble damages, disgorgement of ANI profits, and legal fees) of an unspecified amount. Discovery in this action closed on March 31, 2019 and trial was scheduled to commence on August 25, 2021. On August 3, 2021, the Company entered into a Settlement Agreement with Arbor Pharmaceuticals, LLC to resolve all claims related to Civil Action 17-4910, Arbor Pharmaceuticals, LLC (“Arbor”) v. ANI Pharmaceuticals, Inc., which was pending trial in the United States District Court for the District of Minnesota. Under the terms of the agreement, ANI paid Arbor $8.4 million and Arbor dismissed the action with prejudice. Neither party admitted wrongdoing in reaching this settlement. The Company paid the settlement from cash on the balance sheet On December 3, 2020, class action complaints were filed against the Company on behalf of putative classes of direct and indirect purchasers of the drug Bystolic. On December 23, 2020, six individual purchasers of Bystolic, CVS, Rite Aid, Walgreen, Kroger, Albertsons, and H-E-B, filed complaints against the Company. On March 15, 2021, the plaintiffs in these actions filed amended complaints. All amended complaints are substantively identical. The plaintiffs in these actions allege that, beginning in 2012, Forest Laboratories, the manufacturer of Bystolic, entered into anticompetitive agreements when settling patent litigation related to Bystolic with seven potential manufacturers of a generic version of Bystolic: Hetero, Torrent, Alkem/Indchemie, Glenmark, Amerigen, Watson, and various of their corporate parents, successors, subsidiaries, and affiliates. ANI itself was not a party to patent litigation with Forest concerning Bystolic and did not settle patent litigation with Forest. The plaintiffs named the Company as a defendant based on the Company’s January 8, 2020 Asset Purchase Agreement with Amerigen. The complaints alleged that the 2013 patent litigation settlement agreement between Forest and Amerigen violated federal and state antitrust laws and state consumer protection laws by delaying the market entry of generic versions of Bystolic. Plaintiffs alleged they paid higher prices as a result of delayed generic competition. Plaintiffs sought damages, trebled or otherwise multiplied under applicable law, injunctive relief, litigation costs and attorneys’ fees. The complaints did not specify the amount of damages sought from the Company or other defendants and the Company at this early stage of the litigation cannot reasonably estimate the potential damages that the plaintiffs will seek. The cases have been consolidated in the United States District Court for the Southern District of New York On March 24, 2021, Azurity Pharmaceuticals, Inc. (“Azurity”) filed a complaint in the United States District Court for the District of Minnesota against ANI Pharmaceuticals, Inc., asserting that ANI’s vancomycin hydrochloride oral solution drug product infringes U.S. Patent No. 10,688,046. The complaint sought injunctive relief, damages, including lost profits and/or royalty, treble damages, and attorneys’ fee and costs. On February 15, 2022, the Company entered into a settlement agreement with Azurity to resolve all claims related to this action. Under the terms of the agreement, Azurity granted ANI a non-exclusive, non-transferable, non-sublicensable, royalty-bearing license under its Patents to sell ANI product in the United States and dismissed the action with prejudice. In exchange, we paid Azurity On April 1, 2021, United Therapeutics Corp. and Supernus Pharmaceuticals, Inc. (“UTC/Supernus”) filed a complaint in the United States District Court for the District of Delaware against ANI Pharmaceuticals, Inc., asserting that ANI’s proposed Treprostinil extended release drug product, which is subject to ANI’s Abbreviated New Drug Application No. 215667, infringes U.S. Patent Nos. 7,417,070, 7,544,713, 8,252,839, 8,349,892, 8,410,169, 8,747,897, 9,050,311, 9,278,901, 9,393,203, 9,422,223, 9,593,066 and 9,604,901 (“the Asserted Patents”). The complaint seeks injunctive relief , attorneys' fee and costs. ANI filed its answer and counterclaims on May 28, 2021, denying UTC/Supernus’ allegations and seeking declaratory judgment that ANI has not infringed any valid and enforceable claim of the Asserted Patents, that the Asserted Patents are invalid, and an award of attorneys’ fees and costs. On May 26, 2022, the parties’ respective claims and counterclaims were dismissed pursuant to a confidential settlement agreement. On October 3, 2022, Azurity Pharmaceuticals, Inc. filed a complaint in the United States District Court for the District of New Jersey against ANI’s wholly owned subsidiary, Novitium Pharma, LLC, asserting that Novitium’s manufacture, use, sale, importation and/or offer to sell Bionpharma Inc.’s (“Bionpharma”) enalapril maleate oral solution drug product (the “Product”) infringes U.S. Patents No. 11,040,023 and 11,141,405. The complaint seeks injunctive relief, and an award of Azurity’s costs and expenses. On October 12, 2022, Bionpharma filed a motion in United States District Court for the District of New Jersey to intervene on Novitium’s behalf in the litigation and on October 14, 2022, Novitium and Bionpharma filed a joint motion to transfer venue to the District of Delaware. These motions are still pending. Bionpharma has agreed to indemnify Novitium under the terms of its manufacturing and supply agreement for any damages, costs and expenses relating to actual or alleged infringement of intellectual property rights or sale of the Product by Bionpharma. ANI and Novitium dispute any liability in this matter. Ranitidine Related Litigation State of New Mexico Litigation In re Zantac multidistrict litigation (“MDL”) pending in the United States District Court for the Southern District of Florida. New Mexico moved for remand to state court. The MDL court granted the remand motion on February 25, 2021. On April 16, 2021, New Mexico filed an amended complaint in the New Mexico First Judicial District Court in Santa Fe County. It did not name ANI in the amended complaint, effectively voluntarily dismissing ANI from the action. Novitium is named as a Defendant in the amended complaint. According to Novitium’s records, Novitium did not ship any ranitidine product to New Mexico, and received no funds from any state funded health care plan or Medicaid. The Defendants filed a motion to dismiss the claims asserted in the New Mexico litigation based primarily on preemption. The motion was denied in August 2021. A motion for reconsideration was denied on September 22, 2022. The case is currently in discovery. Federal Court Personal Injury Litigation Koepsel v. Boehringer Ingelheim Pharmaceuticals, et al. Koepsel In re Zantac MDL Koepsel ANI and Novitium were named in other individual personal injury complaints filed in MDL 20 MD 2924 in which plaintiffs allege that they developed cancer after taking prescription and over the counter medication containing ranitidine. ANI was served with complaints in five of those additional cases: Cooper v. Boehringer Ingelheim Pharmaceuticals, et al. Lineberry v. Amneal Pharmaceuticals, LLC, et al. Lovette v. Amneal Pharmaceuticals, LLC, et al. Hightower v. Pfizer, et al, Bird v. Boehringer Ingelheim Pharmaceuticals, et al. Cooper Lineberry Lovette Bird Hightower Novitium has been named in 158 short form complaints filed by claimants in the MDL. Those complaints were effectively dismissed with prejudice with the MPIC on July 8, 2021. Counsel for the plaintiffs have been notified that Novitium did not sell an over the counter ranitidine product and sold a generic prescription ranitidine product for a limited period of time, from December 2018 until September 2019. Novitium’s product was voluntarily recalled in October 2019. Out of the 158 short form complaints, approximately 114 plaintiffs either were diagnosed with cancer before Novitium began manufacturing the product, only took over the counter ranitidine, or took ranitidine before Novitium began manufacturing it. Two of those 114 plaintiffs dismissed Novitium from their short form complaints. In light of the Court’s dismissal of all claims with prejudice, Novitium has not pursued dismissal of the short form complaints against it at this time. State Court Personal Injury Litigation Illinois Ross v. Boehringer Ingelheim Pharmaceuticals, Inc., et. al In August 2022, the Keller Postman law firm commenced six multi-plaintiff actions in Illinois state court naming generic ranitidine manufacturers, including ANI and/or Novitium, as defendants. Those cases are: (1) Jodee Gillespie v. Walgreen Co., et. al. , Circuit Court of the Third Judicial Circuit, Madison County, Illinois, Case No. 2022LA001007 (naming both Novitium and ANI); (2) John Jackson v. Walgreen Co., et. al. , Circuit Court of the Third Judicial Circuit, Madison County, Illinois, Case No. 2022LA001012 (naming Novitium); (3) Ayesha Salahuddin v. Walgreen Co., et. al., Circuit Court of the Twentieth Judicial Circuit, St. Clair County, Illinois, Case No. 22LA0709 (naming Novitium); (4) Lashanda McGruder v. Walgreen Co., et. al., Circuit Court of the Third Judicial Circuit, Madison County, Illinois, Case No. 22LA0710 (naming both Novitium and ANI); (5) Richard Devriendt v. Walgreen Co., et. al., Circuit Court of Cook County, Illinois, Case No. 2022L007429 (naming Novitium); (6) Anthony Stigger v. Walgreen Co., et. al., Circuit Court of Cook County, Illinois, Case No. 2022L007396 (naming both Novitium and ANI). The complaints allege causes of action for failure to warn, design defect, general negligence, loss of consortium and wrongful death. Pursuant to an Order of the Illinois Supreme Court dated October 25, 2022, the pending ranitidine personal injury actions in Illinois have been consolidated in Cook County for coordinated pre-trial proceedings. Responsive pleadings are not yet due. California. In August and September 2022, the Keller Postman law firm commenced seven multi-plaintiff actions in California state court, Alameda County, naming generic ranitidine manufacturers, including ANI and/or Novitium, as defendants. Those cases are: (1) Carlos Ascencio v. ANI Pharmaceuticals, et. al., Superior Court of California, County of Alameda, Case. No. 22CV016230 (naming both Novitium and ANI); (2) Andre Lebeau v. Actavis Mid Atlantic, LLC et. al., Superior Court of California, County of Alameda, Case No. 22CV016448 (naming Novitium); (3) Roque Torres v. ANI Pharmaceuticals, Inc., et. al., Superior Court of California, County of Alameda, Case No. 22CV016338 (naming both Novitium and ANI); (4) Deborah Hinds v. ANI Pharmaceuticals, Inc., et. al., Superior Court of California, County of Alameda, Case No. 22CV016123 (naming both Novitium and ANI); (5) Mark Cruz v. ANI Pharmaceuticals, Inc., et. al., Superior Court of California, County of Alameda, Case No. 22CV016338 (naming both Novitium and ANI); (6) Bent Olsen v. ANI Pharmaceuticals, Inc., et. al., Superior Court of California, County of Alameda, Case No. 22CV016402 (naming both Novitium and ANI); (7) John Norman v. Actavis Mid Atlantic, LLC, et. al., Superior Court of California, County of Alameda, Case No. 22CV018334 (naming Novitium). The complaints allege causes of action for failure to warn, design defect, general negligence, loss of consortium and wrongful death. Responsive pleadings are not yet due. Pennsylvania . In September 2022, two single-plaintiff complaints were filed in Pennsylvania state court, Philadelphia County, naming Novitium as a defendant: (1) William Titus v. Glaxo SmithKline LLC, et. al. , Court of Common Pleas, Philadelphia County, Pennsylvania, Case No. 220902548; and (2) Jodi Woodard v. Ajanta Pharma USA, Inc., et. al. , Court of Common Pleas, Philadelphia County, Pennsylvania, Case No. 220902329. These complaints allege causes of action for negligence, failure to warn, negligent storage and transportation, breach of express and implied warranties, negligent misrepresentation, and fraud. Responsive pleadings are not yet due. ANI and Novitium dispute any liability in these matters. Other Industry Related Matters On or about September 20, 2017, the Company and certain of its employees were served with search warrants and/or grand jury subpoenas to produce documents and possibly testify relating to a federal investigation of the generic pharmaceutical industry. We have been cooperating and intend to continue cooperating with the investigation. However, no assurance can be given as to the timing or outcome of the investigation.

FAIR VALUE DISCLOSURES

FAIR VALUE DISCLOSURES	9 Months Ended
FAIR VALUE DISCLOSURES	Sep. 30, 2022
FAIR VALUE DISCLOSURES
FAIR VALUE DISCLOSURES	14. FAIR VALUE DISCLOSURES Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value. The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair market values are based on period-end statements supplied by the various banks and brokers that held the majority of our funds. The fair value of short-term financial instruments (primarily accounts receivable, prepaid expenses, accounts payable, accrued expenses, and other current liabilities) approximate their carrying values because of their short-term nature. The Term Facility bears an interest rate that fluctuates with the changes in LIBOR and, because the variable interest rates approximate market borrowing rates available to us, we believe the carrying values of these borrowings approximated their fair values at September 30, 2022. Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Contingent Value Rights Our contingent value rights (“CVRs”), which were granted coincident with our merger with BioSante and expire in June 2023, are considered contingent consideration and are classified as liabilities. As such, the CVRs were recorded as purchase consideration at their estimated fair value, using level 3 inputs, and are marked to market each reporting period until settlement. The fair value of CVRs is estimated using the present value of our projection of the expected payments pursuant to the terms of the CVR agreement, which is the primary unobservable input. If our projection or expected payments were to increase substantially, the value of the CVRs could increase as a result. The present value of the liability was calculated using a discount rate of 15%. We determined that the fair value of the CVRs was immaterial as of September 30, 2022 and December 31, 2021. We also determined that the changes in such fair value were immaterial in the three and nine months ended September 30, 2022 and 2021. Interest Rate Swap The fair value of our interest rate swap is estimated based on the present value of projected future cash flows using the LIBOR forward rate curve. The model used to value the interest rate swap includes inputs of readily observable market data, a Level 2 input. As described in detail in Note 6, the fair value of the interest rate swap was a $9.4 million asset as of September 30, 2022. Contingent Consideration In connection with the acquisition of Novitium, we may pay up to $46.5 million in additional consideration related to the achievement of certain milestones, including milestones on gross profit of Novitium portfolio products over a 24-month period, regulatory filings completed during this 24-month period, and a percentage of net profits on certain products that are launched in the future. The discounted cash flow method used to value this contingent consideration includes inputs of not readily observable market data, which are Level 3 inputs. The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: Payment Type Valuation Technique Unobservable Input Assumptions Profit-based milestone payments Probability-weighted discounted cash flow Discount rate 13.2% Projected fiscal year of payment 2023-2029 Product development-based milestone payments Probability-weighted discounted cash flow Discount rate 8.7% Probability of payment 90.0% Projected fiscal year of payment 2023-2024 The following table presents the changes in contingent consideration balances classified as Level 3 balances for the three and nine months ended September 30, 2022 and 2021: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2022 2021 2022 2021 Beginning balance $ 30,958 $ — $ 31,000 $ — Measurement period adjustment — — 300 — Change in fair value 2,476 — 2,134 — Ending balance $ 33,434 $ — $ 33,434 $ — The following table presents our financial assets and liabilities accounted for at fair value on a recurring basis as of September 30, 2022 and December 31, 2021, by level within the fair value hierarchy: (in thousands) Fair Value at Description September 30, 2022 Level 1 Level 2 Level 3 Assets Interest rate swap $ 9,373 $ — $ 9,373 $ — Liabilities Contingent consideration $ 33,434 $ — $ — $ 33,434 CVRs $ — $ — $ — $ — Fair Value at Description December 31, 2021 Level 1 Level 2 Level 3 Liabilities Contingent consideration $ 31,000 $ — $ — $ 31,000 Interest rate swaps $ 6,790 $ — $ 6,790 $ — CVRs $ — $ — $ — $ — Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis We do not have any financial assets and liabilities that are measured at fair value on a non-recurring basis. Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis We do not have any non-financial assets and liabilities that are measured at fair value on a recurring basis. Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis We measure our long-lived assets, including property, plant, and equipment, ROU assets, intangible assets, and goodwill, at fair value on a non-recurring basis. These assets are recognized at fair value when they are deemed to be other-than-temporarily impaired. No such fair value impairment was recognized in the three and nine months ended September 30, 2022 and 2021. Acquired Non-Financial Assets Measured at Fair Value In April 2021, we acquired three NDAs and an ANDA and certain related inventories from Sandoz, Inc. for total consideration of $20.7 million. We also incurred and paid $0.4 million in transaction costs directly related to the acquisition. The acquisition was funded via borrowings under the revolving facility portion of our prior credit facility. We accounted for this transaction as an asset acquisition and capitalized the transaction costs directly related to the acquisition. We recognized $11.4 million as acquired intangible assets and $9.7 million of inventory at fair value, including $0.6 million of API, $1.0 million of sample inventory, and $8.1 million in finished goods inventory. In order to determine the fair value of the intangible assets, we used the present value of the estimated cash flows related to the product rights using a discount rate of 10% , which are level 3 unobservable inputs. On July 21, 2022, we acquired four ANDAs from Oakrum Pharma, LLC for total consideration of $8.0 million plus an immaterial amount for the purchase of finished goods inventory. The transaction was funded from cash on hand. We accounted for this transaction as an asset acquisition and capitalized the transaction costs directly related to the acquisition. The product portfolio included one commercial product, one approved product with a launch completed in September and two filed products, with approval pending. We recognized $7.2 million as acquired ANDA intangible assets and $1.2 million as research and development expense because certain of the generic products have significant remaining work required in order to be commercialized and the products do not have an alternative future use. The payment was allocated to the acquired intangible assets and in-process research and development based on relative fair value, which was determined using Level 3 unobservable inputs. We used the present value of the estimated cash flows related to the products, using a discount rate of 13% to determine the fair value of the acquired intangible assets and in-process research and development. The inventory acquired was immaterial. Contingent liabilities are accrued when they are both estimable and probable. As of September 30, 2022, we accrued $0.2 million in contingent payments due to a third party upon the launch of a product completed in September. This was accrued and recorded in the fair value of acquired intangible assets as it was probable at the acquisition date. The ANDA’s will be amortized in full over its useful life of seven years and will be tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable. No such triggering events were identified during the period from the date of acquisition to September 30, 2022, and therefore no impairment loss was recognized for the nine months ended September 30, 2022.

PURIFIED CORTROPHIN GEL PRE-LAU

PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES	9 Months Ended
PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES	Sep. 30, 2022
PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES
PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES	15. PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES In January 2016, we acquired the right, title and interest in the NDAs for Cortrophin Gel and Cortrophin-Zinc. Subsequently, we assembled a Cortrophin Gel re-commercialization team of scientists, executed a long-term supply agreement with a supplier of pig pituitary glands, our primary raw material for corticotrophin API, executed a long-term supply agreement with an API manufacturer, with whom we have advanced the manufacture of corticotropin API via manufacture of commercial-scale batches, and executed a long-term commercial supply agreement with a current good manufacturing practice (“cGMP”) aseptic fill contract manufacturer. Prior to the third quarter 2019, all purchases of material, including pig pituitary glands and API, related to the re-commercialization efforts were consumed in research and development activities and recognized as research and development expense in the period in which they were incurred. In the third quarter of 2019, we began purchasing materials that are intended to be used commercially in anticipation of FDA approval of Cortrophin Gel and the resultant product launch. The FDA granted approval of the sNDA of this product on October 29, 2021. Prior to FDA approval, under U.S. GAAP, we were prohibited from capitalizing these pre-launch purchases of materials as inventory, and accordingly, they were charged to expense in the period in which they were incurred. Subsequent to approval, these purchases are recorded as inventory at net realizable value. During the three and nine months ended September 30, 2021, we recognized $0.2 million and $0.8 million, respectively, of charges related to purchases of pre-launch materials.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
RELATED PARTY TRANSACTIONS	Sep. 30, 2022
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	16. RELATED PARTY TRANSACTIONS On March 8, 2021, we entered into an Equity Commitment and Investment Agreement with the PIPE Investor, pursuant to which we agreed to issue and sell 25,000 shares of our PIPE Shares for a purchase price of $1,000 per share and an aggregate purchase price of $25.0 million. This agreement closed and the shares were sold and issued for $25.0 million on November 19, 2021. The Chairman of our board of directors is an operating partner of Ampersand Capital Partners, an affiliate of the PIPE Investor. In connection with our acquisition of Novitium, we entered into employment agreements with the two executives and founders of Novitium, Muthusamy Shanmugam and Chad Gassert. Both serve as executive officers of the Company and Mr. Shanmugam also serves on the Company’s board of directors. Mr. Shanmugam holds a minority interest in Scitus Pharma Services (“Scitus”), which provides clinical research services to Novitium; majority interest in SS Pharma LLC (“SS Pharma”), which acquires and supplies API to Novitium; majority interest in Esjay Pharma LLC (“Esjay”), which provided research and development and facilities consulting services; and a minority interest in Nuray Chemical Private Limited (“Nuray”), which manufactures and supplies API to Novitium. During the three months ended September 30, 2022, Esjay no longer provided research and development and facilities consulting services to Novitium or ANI. Mr. Gassert holds a minority interest in Scitus. During the three months ended September 30, 2022, we paid Nuray an immaterial amount, paid SS Pharma $0.8 million, and paid Scitus $0.5 million. During the three months ended September 30, 2022, there were no payments to Esjay. During the nine months ended September 30, 2022, we paid Esjay $0.1 million, paid SS Pharma $2.5 million, paid Nuray $0.9 million, and paid Scitus $1.9 million. As of September 30, 2022, the outstanding balance due to Scitus was $0.2 million and the outstanding balance due to SS Pharma was $1.1 million. As of September 30, 2022, there were no outstanding

SEGMENT REPORTING

SEGMENT REPORTING	9 Months Ended
SEGMENT REPORTING	Sep. 30, 2022
SEGMENT REPORTING
SEGMENT REPORTING	17. SEGMENT REPORTING An operating segment is defined as a component of an entity that engages in business activities from which it may recognize revenues and incur expense, its operating results are regularly reviewed by the entity’s chief operating decision maker (“CODM”) to make decisions about resources to be allocated to the segment and assess its performance, and its discrete financial information is available. Prior to 2022, based on this definition, we had concluded that we had one operating segment. Prior period segment disclosures have been recast for the new segment presentation. Effective in the first quarter of 2022 and prospectively, in conjunction with the principal completion of our buildout of infrastructure in the areas of commercialization of rare disease therapies and the launch of Cortrophin Gel, we determined that we have two operating segments as follows: ● Generics, Established Brands, and Other – Consists of operations related to the development, manufacturing, and marketing of generic and established brand pharmaceuticals, including those sold through traditional channels, contract manufactured products, product development services, royalties, and other. ● Rare Disease – Consists of operations related to the development, manufacturing and marketing of pharmaceuticals used in the treatment of patients with rare conditions. The rare disease segment currently consists of operations related to Cortrophin Gel. Our CODM evaluates our two operating segments based on revenues and earnings before interest, income taxes, depreciation, and amortization (“EBITDA”), exclusive of corporate expenses and other expenses not directly allocated or attributable to an operating segment. These expenses include, but are not limited to, certain management, legal, accounting, human resources, insurance, and information technology expenses. We do not manage assets of the Company by operating segment and our CODM does not review asset information by operating segment. Accordingly, we do not present total assets by operating segment. Financial information by reportable segment, including historical information that has been retroactively re-cast to reflect our two operating segments, is as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2022 2021 2022 2021 Net Revenues Generics, Established Brands, and Other $ 71,219 $ 52,061 $ 198,057 $ 155,207 Rare Disease 12,602 — 24,096 — Total net revenues $ 83,821 $ 52,061 $ 222,153 $ 155,207 Segment earnings/(loss) before interest, taxes, depreciation and amortization (“EBITDA”) and reconciliation to (loss)/income before income taxes Generics, Established Brands, and Other 22,099 17,030 52,103 53,529 Rare Disease (2,382) (3,085) (19,493) (8,836) Depreciation and amortization (14,167) (11,346) (42,488) (33,568) Corporate and other unallocated expenses (1) (10,545) (6,161) (27,225) (27,195) Total operating loss $ (4,995) $ (3,562) $ (37,103) $ (16,070) Interest expense, net (7,264) (2,497) (20,546) (7,482) Other income/(expense), net 37 (1,071) 712 (1,653) Loss before benefit for income taxes $ (12,222) $ (7,130) $ (56,937) $ (25,205) (1) Includes expenses not directly allocated or attributable to a reporting segment, including certain management, legal, accounting, human resources, insurance, and information technology expenses, and are included in selling, general, and administrative expenses in our unaudited interim consolidated statement of operations. Geographic Information Our operations are located in the United States, Canada, and India. The majority of the assets of the Company are located in the United States. The following table depicts the Company’s revenue by geographic operations during the following periods: (in thousands) Three Months Ended September 30, Nine Months Ended September 30, Location of Operations 2022 2021 2022 2021 United States $ 82,851 $ 51,100 $ 219,422 $ 152,007 Canada 970 961 2,731 3,200 Total Revenue $ 83,821 $ 52,061 $ 222,153 $ 155,207 The following table depicts the Company’s property and equipment, net according to geographic location as of: (in thousands) September 30, 2022 December 31, 2021 United States $ 38,932 $ 38,564 Canada (1) 3,328 13,831 India 570 276 Total property and equipment, net $ 42,830 $ 52,671 (1) Amounts as of September 30, 2022 exclude the land and building at our Canada facility, which are classified as held for sale as of September 30, 2022. These assets have a carrying value of $8.0 million .

BUSINESS, PRESENTATION, AND R_2

BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS (Policies)	9 Months Ended
	Sep. 30, 2022
BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS
Organization and Business	Overview ANI Pharmaceuticals, Inc. and its consolidated subsidiaries (together, “ANI,” the “Company,” “we,” “us,” or “our”) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals, including for diseases with high unmet medical need. Our team is focused on delivering growth by building a successful Purified Cortrophin Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our manufacturing capabilities. Our four pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, one is located in East Windsor, New Jersey, and one is located in Oakville, Ontario, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. On June 2, 2022, we announced that we intend to cease operations at our Oakville, Ontario, Canada manufacturing plant by first quarter 2023. This action is part of ongoing initiatives to capture operational synergies following our acquisition of Novitium Pharma LLC (“Novitium”) in November 2021. We are in the process of transitioning the majority of products manufactured or packaged in Oakville to one of our three U.S.-based manufacturing sites, and we are seeking to find potential buyers for the Oakville site. Our operations are subject to certain risks and uncertainties including, among others, current and potential competitors with greater resources, dependence on significant customers, and possible fluctuations in financial results. The accompanying unaudited interim condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations, and potential other funding sources, including cash on hand, to meet our obligations as they become due. We believe the going-concern basis is appropriate for the accompanying unaudited interim condensed consolidated financial statements based on our current operating plan and business strategy for the 12 months following the issuance of this report. As we continue to invest in our Rare Disease segment, we reported net losses of $8.6 million and $43.7 million for the three and nine months ended September 30, 2022, respectively, and the Accumulated Deficit as of September 30,2022 was $92.6 million. Despite those results, we believe that our financial resources, consisting of current working capital, anticipated future operating revenue and corresponding collections from customers, and our Credit Facility, under which $40.0 million remains available for borrowing as of September 30, 2022, will be sufficient to enable us to meet our working capital requirements and debt obligations for at least the next 12 months.
Basis of Presentation	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain prior period information has been reclassified to conform to the current period presentation. In our opinion, the accompanying unaudited interim condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations, comprehensive income/(loss), and cash flows. The consolidated balance sheet at December 31, 2021 has been derived from audited financial statements as of that date. The unaudited interim condensed consolidated statements of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the U.S. Securities and Exchange Commission (the “SEC”). We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim condensed consolidated financial statements are read in conjunction with the audited financial statements and notes previously distributed in our Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Form 10-K”).
Principles of Consolidation	Principles of Consolidation The unaudited interim condensed consolidated financial statements include the accounts of ANI Pharmaceuticals, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.
Foreign Currency	Foreign Currency We have subsidiaries located in Canada and India. The Canada-based subsidiary conducts its transactions in U.S. dollars and Canadian dollars, but its functional currency is the U.S. dollar. The Indian-based subsidiary generally conducts its transactions in Indian rupees, which is also its functional currency. The results of any non-U.S. dollar transactions and balances are remeasured in U.S. dollars at the applicable exchange rates during the period and resulting foreign currency transaction gains and losses are included in the determination of net income. Our gain or loss on transactions denominated in foreign currencies and the translation impact of local currencies to U.S. dollars was immaterial for the three and nine months ended September 30, 2022 and 2021. Unless otherwise noted, all references to “$” or “dollar” refer to the U.S. dollar.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the condensed consolidated financial statements, estimates are used for, but not limited to, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, income tax provision or benefit, deferred taxes and valuation allowance, stock-based compensation, revenue recognition, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, including contingent consideration in acquisitions, fair value of long-lived assets, determination of right-of-use assets and lease liabilities, allowance for credit losses, purchase price allocations, and the depreciable lives of long-lived assets. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness.
Restructuring Activities	Restructuring Activities We define restructuring activities to include costs directly associated with exit or disposal activities. Such costs include cash employee contractual severance and other termination benefits, one-time employee termination severance and benefits, contract termination charges, impairment and acceleration of depreciation associated with long-lived assets, and other exit or disposal costs. In general, we record involuntary employee- related exit and disposal costs when there is a substantive plan for employee severance and related payments are probable and estimable. For one-time termination benefits, including those with a service requirement, expense is recorded when the employees are entitled to receive such benefits and the amount can be reasonably estimated. Expense related to one-time termination benefits with a service requirement is recorded over time, as the service is completed. Contract termination fees and penalties, and other exit and disposal costs are generally recorded as incurred. Restructuring activities are recognized as an operating expense in our consolidated statement of operations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recent Accounting Pronouncements Not Yet Adopted We have evaluated all issued and unadopted Accounting Standards Updates and believe the adoption of these standards will not have a material impact on our condensed consolidated statements of operations, comprehensive income, balance sheets, or cash flows.

REVENUE RECOGNITION AND RELAT_2

REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables)	9 Months Ended
REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables)	Sep. 30, 2022
REVENUE RECOGNITION AND RELATED ALLOWANCES
Schedule of disaggregation of revenue and revenue recognized	Three Months Ended Nine Months Ended Products and Services September 30, September 30, September 30, September 30, (in thousands) 2022 2021 2022 2021 Sales of generic pharmaceutical products $ 53,136 $ 35,140 $ 152,106 $ 101,952 Sales of established brand pharmaceutical products 9,816 14,313 26,731 32,868 Sales of rare disease pharmaceutical products 12,602 — 24,096 — Sales of contract manufactured products 4,779 2,382 12,072 7,277 Royalties from licensing agreements 1,821 — 3,918 11,210 Product development services 1,503 77 2,600 332 Other 164 149 630 1,568 Total net revenues $ 83,821 $ 52,061 $ 222,153 $ 155,207 Three Months Ended Nine Months Ended Timing of Revenue Recognition September 30, September 30, September 30, September 30, (in thousands) 2022 2021 2022 2021 Performance obligations transferred at a point in time $ 82,318 $ 51,984 $ 219,553 $ 154,875 Performance obligations transferred over time 1,503 77 2,600 332 Total $ 83,821 $ 52,061 $ 222,153 $ 155,207
Schedule of accruals and allowances	The following table summarizes activity in the consolidated balance sheets for accruals and allowances for the nine months ended September 30, 2022 and 2021, respectively: Accruals for Chargebacks, Returns, and Other Allowances Administrative Prompt Government Fees and Other Payment (in thousands) Chargebacks Rebates Returns Rebates Discounts Balance at December 31, 2020 $ 88,746 $ 7,826 $ 27,155 $ 8,906 $ 3,839 Accruals/Adjustments 343,117 31,515 16,043 74,594 31,138 Credits Taken Against Reserve (333,867) (27,628) (10,969) (75,877) (30,876) Balance at September 30, 2021 (1) $ 97,996 $ 11,713 $ 32,229 $ 7,623 $ 4,101 Balance at December 31, 2021 $ 94,066 $ 5,492 $ 35,831 $ 13,100 $ 4,642 Accruals/Adjustments 480,626 14,104 18,751 30,475 15,746 Credits Taken Against Reserve (480,203) (10,851) (20,598) (28,766) (15,751) Balance at September 30, 2022 (1) $ 94,489 $ 8,745 $ 33,984 $ 14,809 $ 4,637 (1) Chargebacks are included as an offset to accounts receivable in the unaudited interim condensed consolidated balance sheets. Administrative Fees and Other Rebates and Prompt Payment Discounts are included as an offset to accounts receivable or as accrued expenses and other in the unaudited interim condensed consolidated balance sheets. Returns are included in returned goods reserve in the unaudited interim condensed consolidated balance sheets. Government Rebates are included in accrued government rebates in the unaudited interim condensed consolidated balance sheets.
Schedule of customer concentration	Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 Customer 1 23 % 31 % 26 % 29 % Customer 2 17 % 23 % 18 % 22 % Customer 3 16 % 17 % 15 % 15 %

BUSINESS COMBINATION (Tables)

BUSINESS COMBINATION (Tables)	9 Months Ended
BUSINESS COMBINATION (Tables)	Sep. 30, 2022
BUSINESS COMBINATION
Schedule of purchase consideration	(in thousands) Cash consideration $ 88,109 Repayment of Novitium debts 8,493 Fair value of restricted shares 91,199 Fair value of contingent consideration 30,800 Gross consideration $ 218,601 Cash acquired 12,076 Net consideration $ 206,525
Schedule of purchase price allocation	(in thousands) Total Purchase Consideration $ 218,601 Cash and cash equivalents 12,076 Accounts receivable 27,185 Inventories 14,460 Prepaid expenses and other current assets 1,891 Property and equipment 14,331 Intangible assets 139,200 Goodwill 24,641 Other non-current assets 1,413 Total assets acquired 235,197 Accounts payable 1,560 Accrued expense and other current liabilities 6,035 Accrued compensation and other related expenses 4,909 Accrued government rebates 744 Returned goods reserve 2,202 Other non-current liabilities 1,146 Total liabilities assumed 16,596 Net assets acquired $ 218,601

INDEBTEDNESS (Tables)

INDEBTEDNESS (Tables)	9 Months Ended
INDEBTEDNESS (Tables)	Sep. 30, 2022
INDEBTEDNESS
Schedule of carrying value of the current and non-current components of the term loan	Current September 30, December 31, (in thousands) 2022 2021 Current borrowing on debt $ 3,000 $ 3,000 Deferred financing costs (2,150) (2,150) Current debt, net of deferred financing costs $ 850 $ 850 Non-Current September 30, December 31, (in thousands) 2022 2021 Non-current borrowing on debt $ 294,750 $ 297,000 Deferred financing costs (8,868) (10,480) Non-current debt, net of deferred financing costs and current component $ 285,882 $ 286,520
Schedule of contractual maturity of term loan and DDTL	The contractual maturity of our Term Facility is as follows for the years ending December 31: (in thousands) Term Facility 2022 $ 750 2023 3,000 2024 3,000 2025 3,000 2026 3,000 2027 and thereafter 285,000 Total $ 297,750
Schedule of components of total interest expense related to the notes and term loan	The following table sets forth the components of total interest expense related to the Term Facility during the three and nine months ended September 30, 2022 and interest expense under the Prior Credit Agreement during the three and nine months ended September 30, 2021, as recognized in the accompanying unaudited interim condensed consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, (in thousands) 2022 2021 2022 2021 Contractual coupon $ 6,834 $ 2,342 $ 19,014 $ 7,032 Amortization of finance fees 592 175 1,773 527 Capitalized interest (31) (17) (80) (74) $ 7,395 $ 2,500 $ 20,707 $ 7,485

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	9 Months Ended
EARNINGS (LOSS) PER SHARE (Tables)	Sep. 30, 2022
EARNINGS (LOSS) PER SHARE
Schedule of earnings per share, basic and diluted	Earnings (loss) per share for the three and nine months ended September 30, 2022 and 2021 are calculated for basic and diluted earnings (loss) per share as follows: Basic Diluted Basic Diluted (in thousands, except per share amounts) Three Months Ended September 30, Three Months Ended September 30, Nine Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 2022 2021 2022 2021 Net loss $ (8,600) $ (4,447) $ (8,600) $ (4,447) $ (43,653) $ (18,467) $ (43,653) $ (18,467) Net income allocated to participating securities — — — — — — — — Dividends on Series A convertible preferred stock (406) — (406) — (1,218) — (1,218) — Net loss available to common shareholders $ (9,006) $ (4,447) $ (9,006) $ (4,447) $ (44,871) $ (18,467) $ (44,871) $ (18,467) Basic Weighted-Average Shares Outstanding 16,303 12,107 16,303 12,107 16,238 12,066 16,238 12,066 Dilutive effect of stock options and ESPP — — — — Diluted Weighted-Average Shares Outstanding 16,303 12,107 16,238 12,066 Loss per share $ (0.55) $ (0.37) $ (0.55) $ (0.37) $ (2.76) $ (1.53) $ (2.76) $ (1.53)

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
INVENTORIES (Tables)	Sep. 30, 2022
INVENTORIES
Schedule of Inventories	September 30, December 31, (in thousands) 2022 2021 Raw materials $ 62,423 $ 51,350 Packaging materials 7,871 5,475 Work-in-progress 1,097 652 Finished goods 33,936 31,969 105,327 89,446 Reserve for excess/obsolete inventories (9,434) (7,753) Inventories, net $ 95,893 $ 81,693

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	9 Months Ended
GOODWILL AND INTANGIBLE ASSETS (Tables)	Sep. 30, 2022
GOODWILL AND INTANGIBLE ASSETS
Schedule of components of intangible assets	September 30, 2022 December 31, 2021 Weighted Average Gross Carrying Accumulated Gross Carrying Accumulated Amortization (in thousands) Amount Amortization Amount Amortization Period Definite-Lived Intangible Assets: Acquired ANDA intangible assets $ 189,087 $ (69,824) $ 168,536 $ (54,079) 8.3 years NDAs and product rights 242,372 (156,520) 242,372 (138,835) 9.9 years Marketing and distribution rights 17,157 (13,069) 17,157 (12,347) 5.5 years Non-compete agreement 624 (579) 624 (513) 7.0 years Customer relationships 24,900 (3,261) 24,900 (593) 7.0 years Indefinite-Lived Intangible Assets: In process research and development 33,350 — 46,900 — Indefinite Total Intangible Assets, net $ 507,490 $ (243,253) $ 500,489 $ (206,367) 8.9 years
Schedule of expected future amortization expense	Expected future amortization expense is as follows: (in thousands) 2022 (remainder of the year) $ 12,602 2023 51,792 2024 50,996 2025 48,893 2026 35,574 2027 and thereafter 64,380 Total $ 264,237

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
STOCK-BASED COMPENSATION (Tables)	Sep. 30, 2022
Summary of Stock option and restricted stock activity	A summary of stock option and restricted stock activity under the 2022 Plan and Inducement Grants during the nine months ended September 30, 2022 and 2021 is presented below: (in thousands) Options Inducement Grants RSAs Outstanding at December 31, 2020 756 180 352 Granted 97 61 463 Options Exercised/RSAs Vested (5) — (126) (1) Forfeited (74) — (61) Expired — — — Outstanding at September 30, 2021 774 241 628 Outstanding at December 31, 2021 747 241 707 Granted 36 — 723 Options Exercised/RSAs Vested (16) — (234) (2) Forfeited (58) — (46) Expired — — — Outstanding at September 30, 2022 709 241 1,150 (1) Includes 28 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $0.9 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets. (2) Includes 63 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $1.9 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets .
2016 Employee Stock Purchase Plan
Summary of allocated expense	(in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cost of sales $ 11 $ 3 $ 40 $ 11 Research and development 10 5 31 16 Selling, general, and administrative 82 20 142 66 $ 103 $ 28 $ 213 $ 93
2022 Plan
Summary of allocated expense	(in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cost of sales $ 134 $ 2 $ 393 $ 4 Research and development 186 144 531 407 Selling, general, and administrative 3,447 2,634 9,725 7,017 $ 3,767 $ 2,780 $ 10,649 $ 7,428

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
COMMITMENTS AND CONTINGENCIES (Tables)	Sep. 30, 2022
COMMITMENTS AND CONTINGENCIES
Schedule of rent expense	Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2022 2021 2022 2021 Operating lease costs $ 201 $ 40 $ 470 $ 132 Variable lease costs 53 9 173 30 Total lease costs $ 254 $ 49 $ 643 $ 162
Schedule of maturity analysis of operating leases	(in thousands) Future payments: 2022 $ 175 2023 761 2024 831 2025 431 2026 and thereafter 124 Total $ 2,322 Discount (237) Lease liability 2,085 Current lease liability (604) Non-current lease liability $ 1,481

FAIR VALUE DISCLOSURES (Tables)

FAIR VALUE DISCLOSURES (Tables)	9 Months Ended
FAIR VALUE DISCLOSURES (Tables)	Sep. 30, 2022
FAIR VALUE DISCLOSURES
Schedule of recurring Level 3 fair value measurements of contingent consideration	Payment Type Valuation Technique Unobservable Input Assumptions Profit-based milestone payments Probability-weighted discounted cash flow Discount rate 13.2% Projected fiscal year of payment 2023-2029 Product development-based milestone payments Probability-weighted discounted cash flow Discount rate 8.7% Probability of payment 90.0% Projected fiscal year of payment 2023-2024
Schedule of changes in contingent consideration	Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2022 2021 2022 2021 Beginning balance $ 30,958 $ — $ 31,000 $ — Measurement period adjustment — — 300 — Change in fair value 2,476 — 2,134 — Ending balance $ 33,434 $ — $ 33,434 $ —
Schedule of financial assets and liabilities accounted for at fair value on a recurring basis	(in thousands) Fair Value at Description September 30, 2022 Level 1 Level 2 Level 3 Assets Interest rate swap $ 9,373 $ — $ 9,373 $ — Liabilities Contingent consideration $ 33,434 $ — $ — $ 33,434 CVRs $ — $ — $ — $ — Fair Value at Description December 31, 2021 Level 1 Level 2 Level 3 Liabilities Contingent consideration $ 31,000 $ — $ — $ 31,000 Interest rate swaps $ 6,790 $ — $ 6,790 $ — CVRs $ — $ — $ — $ —

SEGMENT REPORTING (Tables)

SEGMENT REPORTING (Tables)	9 Months Ended
SEGMENT REPORTING (Tables)	Sep. 30, 2022
SEGMENT REPORTING
Schedule of revenue by reportable segments	Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2022 2021 2022 2021 Net Revenues Generics, Established Brands, and Other $ 71,219 $ 52,061 $ 198,057 $ 155,207 Rare Disease 12,602 — 24,096 — Total net revenues $ 83,821 $ 52,061 $ 222,153 $ 155,207 Segment earnings/(loss) before interest, taxes, depreciation and amortization (“EBITDA”) and reconciliation to (loss)/income before income taxes Generics, Established Brands, and Other 22,099 17,030 52,103 53,529 Rare Disease (2,382) (3,085) (19,493) (8,836) Depreciation and amortization (14,167) (11,346) (42,488) (33,568) Corporate and other unallocated expenses (1) (10,545) (6,161) (27,225) (27,195) Total operating loss $ (4,995) $ (3,562) $ (37,103) $ (16,070) Interest expense, net (7,264) (2,497) (20,546) (7,482) Other income/(expense), net 37 (1,071) 712 (1,653) Loss before benefit for income taxes $ (12,222) $ (7,130) $ (56,937) $ (25,205) (1) Includes expenses not directly allocated or attributable to a reporting segment, including certain management, legal, accounting, human resources, insurance, and information technology expenses, and are included in selling, general, and administrative expenses in our unaudited interim consolidated statement of operations.
Schedule of revenue by geographic operations	(in thousands) Three Months Ended September 30, Nine Months Ended September 30, Location of Operations 2022 2021 2022 2021 United States $ 82,851 $ 51,100 $ 219,422 $ 152,007 Canada 970 961 2,731 3,200 Total Revenue $ 83,821 $ 52,061 $ 222,153 $ 155,207
Schedule of property and equipment by geographic location	(in thousands) September 30, 2022 December 31, 2021 United States $ 38,932 $ 38,564 Canada (1) 3,328 13,831 India 570 276 Total property and equipment, net $ 42,830 $ 52,671 (1) Amounts as of September 30, 2022 exclude the land and building at our Canada facility, which are classified as held for sale as of September 30, 2022. These assets have a carrying value of $8.0 million .

BUSINESS, PRESENTATION, AND R_3

BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Debt Instrument [Line Items]
Net loss	$ (8,600)	$ (4,447)	$ (43,653)	$ (18,467)
Accumulated deficit	(92,636)		(92,636)		$ (47,765)
Credit Facility - 2021 \| Revolving Facility
Debt Instrument [Line Items]
Remaining borrowing capacity	$ 40,000		$ 40,000

REVENUE RECOGNITION AND RELAT_3

REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue recognition	$ 83,821	$ 52,061	$ 222,153	$ 155,207
Sales of generic pharmaceutical products
Revenue recognition	53,136	35,140	152,106	101,952
Sales of established brand pharmaceutical products
Revenue recognition	9,816	14,313	26,731	32,868
Sales of rare disease pharmaceutical products
Revenue recognition	12,602		24,096
Sales of contract manufactured products
Revenue recognition	4,779	2,382	12,072	7,277
Royalties from licensing agreements
Revenue recognition	1,821		3,918	11,210
Product development services
Revenue recognition	1,503	77	2,600	332
Other
Revenue recognition	$ 164	$ 149	$ 630	$ 1,568

REVENUE RECOGNITION AND RELAT_4

REVENUE RECOGNITION AND RELATED ALLOWANCES - Timing (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue recognition	$ 83,821	$ 52,061	$ 222,153	$ 155,207
Performance obligations satisfied in prior periods			2,600	8,700
Performance obligations transferred at a point in time
Revenue recognition	82,318	51,984	219,553	154,875
Performance obligations transferred over time
Revenue recognition	1,503	77	2,600	332
Maximum
Revenue recognized	$ 100	$ 100	$ 100	$ 100

REVENUE RECOGNITION AND RELAT_5

REVENUE RECOGNITION AND RELATED ALLOWANCES - Allowances (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Accruals and allowances
Beginning balance	$ 105,260
Ending balance	111,000
Chargebacks
Accruals and allowances
Beginning balance	94,066	$ 88,746
Accruals/Adjustments	480,626	343,117
Credits Taken Against Reserve	(480,203)	(333,867)
Ending balance	94,489	97,996
Government Rebates
Accruals and allowances
Beginning balance	5,492	7,826
Accruals/Adjustments	14,104	31,515
Credits Taken Against Reserve	(10,851)	(27,628)
Ending balance	8,745	11,713
Returns
Accruals and allowances
Beginning balance	35,831	27,155
Accruals/Adjustments	18,751	16,043
Credits Taken Against Reserve	(20,598)	(10,969)
Ending balance	33,984	32,229
Administrative Fees and Other Rebates
Accruals and allowances
Beginning balance	13,100	8,906
Accruals/Adjustments	30,475	74,594
Credits Taken Against Reserve	(28,766)	(75,877)
Ending balance	14,809	7,623
Prompt Payment Discounts
Accruals and allowances
Beginning balance	4,642	3,839
Accruals/Adjustments	15,746	31,138
Credits Taken Against Reserve	(15,751)	(30,876)
Ending balance	$ 4,637	$ 4,101

REVENUE RECOGNITION AND RELAT_6

REVENUE RECOGNITION AND RELATED ALLOWANCES - Concentration (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue recognition	$ 83,821	$ 52,061		$ 222,153	$ 155,207
Tripartite Agreement-Yescart
Revenue recognition			$ 11,200
Payment for legal expenditures			$ 400
Sales of contract manufactured products
Revenue, Remaining Performance Obligation, Amount	$ 7,500			$ 7,500
Revenue, Remaining Performance Obligation, Remaining Period	6 months			6 months
Revenue recognition	$ 4,779	$ 2,382		$ 12,072	$ 7,277
Product Development Services
Revenue, Remaining Performance Obligation, Amount	$ 200			$ 200
Revenue, Remaining Performance Obligation, Remaining Period	6 months			6 months
Customer concentration \| Revenue \| Customer one
Concentration Risk, Percentage	23%	31%		26%	29%
Customer concentration \| Revenue \| Customer two
Concentration Risk, Percentage	17%	23%		18%	22%
Customer concentration \| Revenue \| Customer three
Concentration Risk, Percentage	16%	17%		15%	15%
Customer concentration \| Accounts receivable \| Three Customers
Concentration Risk, Percentage				80%

BUSINESS COMBINATION (Details)

BUSINESS COMBINATION (Details) - Novitium $ / shares in Units, $ in Thousands		12 Months Ended
	Nov. 19, 2021 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) shares	Sep. 30, 2022 USD ($)
Business acquisition
Shares issued in acquisition (in shares) \| shares	2,466,654	2,500,000
Closing stock price \| $ / shares	$ 43.54
Additional contingent consideration	$ 46,500		$ 46,500
Restriction period for shares issued	24 months
Business acquisition purchase consideration
Cash consideration	$ 88,109
Repayment of Novitium debts	8,493
Fair value of restricted shares	91,199
Fair value of contingent consideration	30,800	$ 31,000	$ 33,434
Gross consideration	218,601
Cash acquired	12,076
Net consideration	$ 206,525
Minimum
Business acquisition
Restriction period for shares issued	3 months
Maximum
Business acquisition
Restriction period for shares issued	24 months
Measurement Input, Stock Volatility \| Minimum
Business acquisition purchase consideration
Unobservable inputs	0.65
Measurement Input, Stock Volatility \| Maximum
Business acquisition purchase consideration
Unobservable inputs	0.71
Measurement Input, Discounted Lack of Marketability \| Minimum
Business acquisition purchase consideration
Unobservable inputs	0.075
Measurement Input, Discounted Lack of Marketability \| Maximum
Business acquisition purchase consideration
Unobservable inputs	0.215

BUSINESS COMBINATION - Acquired

BUSINESS COMBINATION - Acquired (Details) - USD ($) $ in Thousands	Nov. 19, 2021	Sep. 30, 2022	Dec. 31, 2021
Goodwill		$ 28,221	$ 27,888
Novitium
Total Purchase Consideration	$ 218,601
Cash and cash equivalents	12,076
Accounts receivable	27,185
Inventories	14,460
Prepaid expenses and other current assets	1,891
Property and equipment	14,331
Intangible assets	139,200
Goodwill	24,641
Other non-current assets	1,413
Total assets acquired	235,197
Accounts payable	1,560
Accrued expense and other current liabilities	6,035
Accrued compensation and other related expenses	4,909
Accrued government rebates	744
Returned goods reserve	2,202
Other non-current liabilities	1,146
Total liabilities assumed	16,596
Net assets acquired	218,601
Novitium \| Acquired ANDA intangible assets
Intangible assets	67,400
Novitium \| Customer relationships
Intangible assets	24,900
Novitium \| In process research and development
Intangible assets	$ 46,900

BUSINESS COMBINATION - Pro Form

BUSINESS COMBINATION - Pro Forma (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Novitium
Revenue since acquisition date	$ 24	$ 63.1

RESTRUCTURING (Details)

RESTRUCTURING (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
RESTRUCTURING (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Restructuring
Restructuring activity expense	$ 1,541		$ 4,111	$ 0
Assets held for sale	8,020		8,020
Oakville, Ontario, Canada
Restructuring
Restructuring activity expense	1,500		4,100
Restructuring accrual	1,100		1,100
Assets held for sale	8,000		8,000
Oakville, Ontario, Canada \| Employee severance and other benefit costs
Restructuring
Restructuring activity expense	400		1,800
Restructuring expected cost remaining	600		600
Oakville, Ontario, Canada \| Asset-related impairment
Restructuring
Restructuring activity expense	1,200		2,100
Oakville, Ontario, Canada \| Asset-related impairment \| Minimum
Restructuring
Restructuring expected cost remaining	1,900		1,900
Oakville, Ontario, Canada \| Asset-related impairment \| Maximum
Restructuring
Restructuring expected cost remaining	$ 2,400		$ 2,400
Oakville, Ontario, Canada \| Other implementation costs
Restructuring
Restructuring activity expense		$ 300

INDEBTEDNESS - Credit facility

INDEBTEDNESS - Credit facility (Details) - USD ($) $ in Thousands		9 Months Ended
	Nov. 19, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Debt
Current debt		$ 850		$ 850
Payments of debt issuance costs		0	$ 262
Term Facility
Debt
Debt, net of issuance costs		297,750
Credit Facility - 2021
Debt
Current debt		$ 3,000
Payments of debt issuance costs	$ 14,000
Credit Facility - 2021 \| Term Facility
Debt
Maximum borrowing capacity	300,000
Debt effective interest rate (as a percent)		9.14%
Quarterly payment	$ 750
Principal amount		$ 297,800
Credit Facility - 2021 \| Term Facility \| Alternative Base Rate
Debt
Basis spread (as a percent)	5%
Credit Facility - 2021 \| Term Facility \| LIBOR
Debt
Basis spread (as a percent)	6%
Credit Facility - 2021 \| Revolving Facility
Debt
Maximum borrowing capacity	$ 40,000
Remaining borrowing capacity		40,000
Commitment fee (as a percent)	0.50%
Deferred debt issuance costs		$ 900
Credit Facility - 2021 \| Revolving Facility \| Alternative Base Rate
Debt
Basis spread (as a percent)	3.75%
Credit Facility - 2021 \| Revolving Facility \| LIBOR
Debt
Basis spread (as a percent)	4.75%

INDEBTEDNESS - Facility compone

INDEBTEDNESS - Facility components (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current debt, net of deferred financing costs	$ 850	$ 850
Non-current debt, net of deferred financing costs and current component	285,882	286,520
Term Loan and DDTL
Current borrowing on debt	3,000	3,000
Deferred financing costs	(2,150)	(2,150)
Current debt, net of deferred financing costs	850	850
Non-current borrowing on debt	294,750	297,000
Deferred financing costs	(8,868)	(10,480)
Non-current debt, net of deferred financing costs and current component	285,882	$ 286,520
Credit Facility - 2021
Current debt, net of deferred financing costs	$ 3,000

INDEBTEDNESS - Outstanding (Det

INDEBTEDNESS - Outstanding (Details) - Credit Facility - 2021 $ in Millions	Sep. 30, 2022 USD ($)
Term Facility
Borrowing on debt	$ 297.8
Revolving Facility
Total debt issuance costs, net	0.9
Debt issuance costs, noncurrent	0.7
Debt issuance costs, current	$ 0.2

INDEBTEDNESS - Credit facilit_2

INDEBTEDNESS - Credit facility - Maturity (Details) - Term Facility $ in Thousands	Sep. 30, 2022 USD ($)
2022	$ 750
2023	3,000
2024	3,000
2025	3,000
2026	3,000
2027 and thereafter	285,000
Total	$ 297,750

INDEBTEDNESS - Interest (Detail

INDEBTEDNESS - Interest (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
INDEBTEDNESS - Interest (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
INDEBTEDNESS
Contractual coupon	$ 6,834	$ 2,342	$ 19,014	$ 7,032
Amortization of finance fees	592	175	1,773	527
Capitalized interest	(31)	(17)	(80)	(74)
Interest Expense, Debt	$ 7,395	$ 2,500	$ 20,707	$ 7,485

DERIVATIVE FINANCIAL INSTRUME_2

DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Apr. 30, 2020
Fair value interest rate derivative assets	$ 9,373		$ 9,373
Accumulated other comprehensive loss, net of tax	(10,039)		(10,039)		$ 3,055
Derivative unrealized gain (loss) recorded in OCI	4,609	$ 1,198	13,094	$ 7,202
Interest rate swap
Derivative liability, notional amount	155,100		155,100			$ 168,600
Debt effective interest rate (as a percent)						2.26%
Decrease in notional amount			4,000
Fair value interest rate derivative assets	9,400		9,400
Accumulated other comprehensive loss, net of tax	10,000		10,000
Derivative unrealized gain (loss)	5,400		15,300
Derivative unrealized gain (loss) recorded in OCI	4,600		13,100
Interest expense	400		2,400
Reclassifications out of accumulated other comprehensive income/loss	700	$ 1,700	2,100	$ 5,500
Interest rate swap \| Credit Facility - 2021
Derivative liability, notional amount	$ 155,100		$ 155,100

EARNINGS (LOSS) PER SHARE (Deta

EARNINGS (LOSS) PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
EARNINGS (LOSS) PER SHARE
Net Loss	$ (8,600)	$ (4,447)	$ (43,653)	$ (18,467)
Dividends on Series A Convertible Preferred Stock	(406)		(1,218)	0
Net loss available to common shareholders, Basic	(9,006)	(4,447)	(44,871)	(18,467)
Net loss available to common shareholders, Diluted	$ (9,006)	$ (4,447)	$ (44,871)	$ (18,467)
Basic Weighted-Average Shares Outstanding	16,303	12,107	16,238	12,066
Diluted Weighted-Average Shares Outstanding	16,303	12,107	16,238	12,066
Loss per share, Basic	$ (0.55)	$ (0.37)	$ (2.76)	$ (1.53)
Loss per share, Diluted	$ (0.55)	$ (0.37)	$ (2.76)	$ (1.53)

EARNINGS (LOSS) PER SHARE - Add

EARNINGS (LOSS) PER SHARE - Additional information (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
EARNINGS (LOSS) PER SHARE
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2.7	1.6	2.7	1.7

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
INVENTORIES
Raw materials	$ 62,423	$ 51,350
Packaging materials	7,871	5,475
Work-in-progress	1,097	652
Finished goods	33,936	31,969
Inventory, Gross, Total	105,327	89,446
Reserve for excess/obsolete inventories	(9,434)	(7,753)
Inventories, net	$ 95,893	$ 81,693

INVENTORIES - Concentration (De

INVENTORIES - Concentration (Details) - Supplier concentration - One supplier $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($) item
Cost of goods sold
Concentration Risk, Percentage	13%
Number of major suppliers \| item	1
Accounts payable
Amount payable to supplier \| $	$ 0

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2018	Dec. 31, 2013
Goodwill, impairment loss	$ 0	$ 0	$ 0	$ 0
BioSante Pharmaceuticals
Acquisition of goodwill							$ 1,800
WellSpring
Acquisition of goodwill						$ 1,700
Novitium
Acquisition of goodwill					$ 24,600

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS - Components (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Jul. 21, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Definite-Lived Intangible Assets:
Accumulated Amortization		$ (243,253)		$ (243,253)		$ (206,367)
Weighted Average Amortization Period				8 years 10 months 24 days
Indefinite-Lived Intangible Assets:
Gross Carrying Amount, total		507,490		$ 507,490		500,489
Amortization of intangible assets		12,500	$ 10,100	36,900	$ 29,800
Intangible asset impairment charge			$ 0	$ 112	$ 0
Minimum
Definite-Lived Intangible Assets:
Weighted Average Amortization Period				7 years
Maximum
Definite-Lived Intangible Assets:
Weighted Average Amortization Period				10 years
In process research and development
Indefinite-Lived Intangible Assets:
Gross Carrying Amount		33,350		$ 33,350		46,900
In process research and development \| Reclassification of Assets on Completion of Project and Launch of Related Products
Definite-Lived Intangible Assets:
Gross Carrying Amount		(13,600)		(13,600)
Acquired ANDA intangible assets \| Reclassification of Assets on Completion of Project and Launch of Related Products
Definite-Lived Intangible Assets:
Gross Carrying Amount		13,600		13,600
Acquired ANDA intangible assets
Definite-Lived Intangible Assets:
Gross Carrying Amount		189,087		189,087		168,536
Accumulated Amortization		(69,824)		$ (69,824)		(54,079)
Weighted Average Amortization Period				8 years 3 months 18 days
Acquired ANDA intangible assets \| Oakrum Pharma
Definite-Lived Intangible Assets:
Gross Carrying Amount	$ 7,200
Weighted Average Amortization Period	7 years
Indefinite-Lived Intangible Assets:
Intangible asset impairment charge				$ 0
Intangible assets acquired		$ 7,200
Acquired ANDA intangible assets \| Reclassification of Assets on Completion of Project and Launch of Related Products
Definite-Lived Intangible Assets:
Weighted Average Amortization Period		7 years
NDAs and product rights
Definite-Lived Intangible Assets:
Gross Carrying Amount		$ 242,372		242,372		242,372
Accumulated Amortization		(156,520)		$ (156,520)		(138,835)
Weighted Average Amortization Period				9 years 10 months 24 days
Marketing and distribution rights
Definite-Lived Intangible Assets:
Gross Carrying Amount		17,157		$ 17,157		17,157
Accumulated Amortization		(13,069)		$ (13,069)		(12,347)
Weighted Average Amortization Period				5 years 6 months
Non-compete agreement
Definite-Lived Intangible Assets:
Gross Carrying Amount		624		$ 624		624
Accumulated Amortization		(579)		$ (579)		(513)
Weighted Average Amortization Period				7 years
Customer relationships
Definite-Lived Intangible Assets:
Gross Carrying Amount		24,900		$ 24,900		24,900
Accumulated Amortization		$ (3,261)		$ (3,261)		$ (593)
Weighted Average Amortization Period				7 years

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS - Amortization (Details) $ in Thousands	Sep. 30, 2022 USD ($)
GOODWILL AND INTANGIBLE ASSETS
2022 (remainder of the year)	$ 12,602
2023	51,792
2024	50,996
2025	48,893
2026	35,574
2027 and thereafter	64,380
Total	$ 264,237

MEZZANINE AND STOCKHOLDERS' E_2

MEZZANINE AND STOCKHOLDERS' EQUITY (Details) $ / shares in Units, $ in Millions			12 Months Ended
	Nov. 19, 2021 USD ($) D $ / shares shares	Mar. 08, 2021 USD ($) $ / shares shares	Dec. 31, 2021 $ / shares shares	Sep. 30, 2022 $ / shares shares	Jun. 30, 2022 shares	Sep. 30, 2021 shares	Jun. 30, 2021 shares	Dec. 31, 2020 shares
Preferred Stock, Shares Authorized			1,666,667	1,666,667
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares			$ 0.0001	$ 0.0001
Convertible Preferred Stock
Convertible preferred stock outstanding (shares)			25,000	25,000	25,000
PIPE Shares \| Convertible Preferred Stock
Temporary stock issued (in shares)	25,000	25,000
Temporary stock issued (in dollars per share) \| $ / shares	$ 1,000	$ 1,000
Temporary stock issued, value \| $	$ 25	$ 25
Cash paid for costs of share issuances \| $	$ 0.2
Shares accrue dividends rate	6.50%
Shares conversion price \| $ / shares	$ 41.47
Threshold number of trading days \| D	20
Number of consecutive trading days \| D	30
Maximum percentage of conversion price	1.70%
Convertible, shares issuable				602,901
Common Stock
Common Stock, Authorized Shares				33,300,000
Common Stock, Par Value (in dollars per share) \| $ / shares				$ 0.0001
Common Stock, Shares, Issued			16,913,000	17,614,000	17,566,000	12,824,000	12,826,000	12,430,000
Common Stock, Shares, Outstanding			16,800,000	17,500,000
Issuance of Common Stock in Public Offering (in shares)			1,500,000
Class C Special Stock
Common Stock, Authorized Shares				800,000
Common Stock, Par Value (in dollars per share) \| $ / shares				$ 0.0001
Common Stock, Shares, Issued				11,000
Common Stock, Shares, Outstanding				11,000
Common Stock Conversion Price \| $ / shares				$ 90
Novitium
Shares issued in acquisition (in shares)	2,466,654		2,500,000

STOCK-BASED COMPENSATION - Expe

STOCK-BASED COMPENSATION - Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
2016 Employee Stock Purchase Plan
Stock-based compensation shares available	200,000		200,000
Discount from market price (as a percent)			15%
Allocated share-based compensation expense	$ 103	$ 28	$ 213	$ 93
2022 Plan
Stock-based compensation shares available	1,000,000		1,000,000
Stock-based compensation additional shares authorized			1,150,000
Allocated share-based compensation expense	$ 3,767	2,780	$ 10,649	7,428
Cost of sales \| 2016 Employee Stock Purchase Plan
Allocated share-based compensation expense	11	3	40	11
Cost of sales \| 2022 Plan
Allocated share-based compensation expense	134	2	393	4
Research and development \| 2016 Employee Stock Purchase Plan
Allocated share-based compensation expense	10	5	31	16
Research and development \| 2022 Plan
Allocated share-based compensation expense	186	144	531	407
Selling, general and administrative \| 2016 Employee Stock Purchase Plan
Allocated share-based compensation expense	82	20	142	66
Selling, general and administrative \| 2022 Plan
Allocated share-based compensation expense	$ 3,447	$ 2,634	$ 9,725	$ 7,017

STOCK-BASED COMPENSATION - Stoc

STOCK-BASED COMPENSATION - Stock option activity (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Options
Option Shares
Outstanding at the beginning of the period (in shares)	747	756
Granted (in shares)	36	97
Exercised (in shares)	(16)	(5)
Forfeited (in shares)	(58)	(74)
Outstanding at the end of the period (in shares)	709	774
Inducement Grants
Option Shares
Outstanding at the beginning of the period (in shares)	241	180
Granted (in shares)		61
Outstanding at the end of the period (in shares)	241	241

STOCK-BASED COMPENSATION - RSA

STOCK-BASED COMPENSATION - RSA activity (Details) - RSAs - shares shares in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Unvested, Shares, Outstanding, Beginning of period	707	352
Unvested Shares, Granted	723	463
Unvested Shares, Vested	(234)	(126)
Unvested Shares, Forfeited	(46)	(61)
Unvested Shares, Outstanding, End of period	1,150	628

STOCK-BASED COMPENSATION - Addi

STOCK-BASED COMPENSATION - Additional information (Details) - USD ($) shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Treasury stock value	$ 4,975		$ 3,135
RSAs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares purchased from employees	63	28
Treasury stock value	$ 1,900	$ 900

INCOME TAXES - Quarter (Details

INCOME TAXES - Quarter (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
INCOME TAXES - Quarter (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
INCOME TAXES
Valuation allowance	$ 400		$ 400
Benefit for income taxes	$ 3,622	$ 2,683	$ 13,284	$ 6,738
Effective income tax rate (as a percent)	29.60%	37.60%	23.30%	26.70%
pre-tax consolidated loss	$ 12,222	$ 7,130	$ 56,937	$ 25,205

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Leases expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating lease, weighted average remaining lease term	2 years 9 months 18 days		2 years 9 months 18 days
Operating lease costs	$ 201	$ 40	$ 470	$ 132
Variable lease costs	53	9	173	30
Total lease costs	$ 254	$ 49	$ 643	$ 162
Minimum
Operating lease liability discount rates (in percent)	3.99%		3.99%
Maximum
Operating lease liability discount rates (in percent)	8.95%		8.95%

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES - Lease maturity (Details) $ in Thousands	Sep. 30, 2022 USD ($)
COMMITMENTS AND CONTINGENCIES
2022	$ 175
2023	761
2024	831
2025	431
2026 and thereafter	124
Total	2,322
Discount	(237)
Lease liability	2,085
Current lease liability	$ (604)
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued Liabilities, Current
Non-current lease liability	$ 1,481

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands			1 Months Ended		2 Months Ended	3 Months Ended		9 Months Ended
COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands	Aug. 03, 2021 USD ($)	Mar. 24, 2021 USD ($)	Sep. 30, 2022 plaintiff	Aug. 31, 2022 plaintiff	Sep. 30, 2022 plaintiff	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)
COMMITMENTS AND CONTINGENCIES
Revenue recognition						$ 83,821	$ 52,061	$ 222,153	$ 155,207
State Court Personal Injury Litigation \| Illinois
COMMITMENTS AND CONTINGENCIES
Number of plaintiffs \| plaintiff				6
State Court Personal Injury Litigation \| California
COMMITMENTS AND CONTINGENCIES
Number of plaintiffs \| plaintiff					7
State Court Personal Injury Litigation \| Pennsylvania
COMMITMENTS AND CONTINGENCIES
Number of plaintiffs \| plaintiff			2
Arbor Pharmaceuticals
COMMITMENTS AND CONTINGENCIES
Settlement amount awarded to other party	$ 8,400
Azurity Pharmaceuticals
COMMITMENTS AND CONTINGENCIES
Settlement amount awarded to other party		$ 1,900
Royalties on future sales (as a percent)		20%
Azurity Pharmaceuticals \| Cost of sales
COMMITMENTS AND CONTINGENCIES
Settlement amount awarded to other party		$ 1,900
Unapproved Products
COMMITMENTS AND CONTINGENCIES
Revenue recognition						3,100	4,200	10,000	12,200
Unapproved Products \| Contract Customer
COMMITMENTS AND CONTINGENCIES
Revenue recognition						$ 1,000	$ 700	$ 2,100	$ 2,100

FAIR VALUE DISCLOSURES - Level

FAIR VALUE DISCLOSURES - Level 3 (Details) $ in Thousands	3 Months Ended		9 Months Ended
FAIR VALUE DISCLOSURES - Level 3 (Details) $ in Thousands	Sep. 30, 2022 USD ($)	Sep. 30, 2021	Sep. 30, 2022 USD ($)	Sep. 30, 2021	Nov. 19, 2021 USD ($)
Changes in contingent consideration
Level 3 liability, beginning balance	$ 30,958		$ 31,000
Measurement period adjustment			300
Change in fair value	$ 2,476		$ 2,134
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability
Level 3 liability, ending balance	$ 33,434		$ 33,434
Discount rate \| Profit-based milestone payments
Unobservable inputs	13.2		13.2
Discount rate \| Product development-based milestone payments
Unobservable inputs	8.7		8.7
Probability of payment \| Product development-based milestone payments
Unobservable inputs	90		90
Contingent Value Rights \| Discount rate
Unobservable inputs	0.15		0.15
Novitium
Additional contingent consideration	$ 46,500		$ 46,500		$ 46,500

FAIR VALUE DISCLOSURES - Hierar

FAIR VALUE DISCLOSURES - Hierarchy (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Nov. 19, 2021
Interest rate swaps, asset	$ 9,373
Interest rate swaps, liability		$ 6,790
Fair Value, Inputs, Level 2 [Member]
Interest rate swaps, asset	9,373
Interest rate swaps, liability		6,790
Novitium
Contingent consideration	33,434	31,000	$ 30,800
Novitium \| Fair Value, Inputs, Level 3 [Member]
Contingent consideration	$ 33,434	$ 31,000

FAIR VALUE DISCLOSURES - Acquir

FAIR VALUE DISCLOSURES - Acquired (Details) $ in Thousands		1 Months Ended	3 Months Ended		9 Months Ended
FAIR VALUE DISCLOSURES - Acquired (Details) $ in Thousands	Jul. 21, 2022 USD ($)	Apr. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Inventories, net			$ 95,893		$ 95,893		$ 81,693
Raw materials			62,423		62,423		51,350
Finished goods			33,936		33,936		31,969
Research and development			7,657	$ 2,456	$ 17,096	$ 8,229
Useful life of intangible assets					8 years 10 months 24 days
Intangible asset impairment charge				$ 0	$ 112	$ 0
Acquired ANDA intangible assets
Finite-lived intangible gross carrying amount			$ 189,087		$ 189,087		$ 168,536
Useful life of intangible assets					8 years 3 months 18 days
Oakrum Pharma \| Acquired ANDA intangible assets
Total asset purchase	$ 8,000
Finite-lived intangible gross carrying amount	7,200
Research and development	$ 1,200
Contingent liability not recognized, asset acquisition					$ 200
Useful life of intangible assets	7 years
Intangible asset impairment charge					0
Oakrum Pharma \| Acquired ANDA intangible assets \| Discount rate
Intangible asset measurement input	0.13
Sandoz
Total asset purchase		$ 20,700
Transaction costs		400
Finite-lived intangible gross carrying amount		11,400
Inventories, net		9,700
Raw materials		600
Sample inventory		1,000
Finished goods		$ 8,100
Useful life of intangible assets		7 years
Intangible asset impairment charge					$ 0
Sandoz \| Discount rate
Intangible asset measurement input		0.10

PURIFIED CORTROPHIN GEL PRE-L_2

PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES
Purified Cortrophin Gel pre-launch charges	$ 227	$ 0	$ 780

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended	9 Months Ended
	Nov. 19, 2021	Mar. 08, 2021	Sep. 30, 2022	Sep. 30, 2022
Convertible Preferred Stock \| PIPE Shares
Related Party Transaction [Line Items]
Temporary stock issued (in shares)	25,000	25,000
Temporary stock issued (in dollars per share)	$ 1,000	$ 1,000
Temporary stock issued, value	$ 25	$ 25
Esjay
Related Party Transaction [Line Items]
Payments to related party			$ 0	$ 0.1
Due to related parties			0	0
SS Pharma
Related Party Transaction [Line Items]
Payments to related party			0.8	2.5
Due to related parties			1.1	1.1
Nuray
Related Party Transaction [Line Items]
Payments to related party				0.9
Due to related parties			0	0
Scitus
Related Party Transaction [Line Items]
Payments to related party			0.5	1.9
Due to related parties			$ 0.2	$ 0.2

SEGMENT REPORTING - Revenue (De

SEGMENT REPORTING - Revenue (Details) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
SEGMENT REPORTING - Revenue (Details) $ in Thousands	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) segment	Sep. 30, 2021 USD ($)	Dec. 31, 2021 segment
Segment reporting
Number of segments \| segment			2		1
Revenue recognition	$ 83,821	$ 52,061	$ 222,153	$ 155,207
Depreciation and amortization	14,167	11,346	42,488	33,568
Selling, general, and administrative	30,081	17,181	90,856	53,588
Operating Loss	(4,995)	(3,562)	(37,103)	(16,070)
Interest expense, net	(7,264)	(2,497)	(20,546)	(7,482)
Other expense, net	37	(1,071)	712	(1,653)
Loss Before Benefit for Income Taxes	(12,222)	(7,130)	(56,937)	(25,205)
Operating segments \| Generics, Established Brands and Other
Segment reporting
Revenue recognition	71,219	52,061	198,057	155,207
EBITDA	22,099	17,030	52,103	53,529
Operating segments \| Rare Disease
Segment reporting
Revenue recognition	12,602		24,096
EBITDA	(2,382)	(3,085)	(19,493)	(8,836)
Unallocated expenses
Segment reporting
Depreciation and amortization	(14,167)	(11,346)	(42,488)	(33,568)
Selling, general, and administrative	(10,545)	(6,161)	(27,225)	(27,195)
Operating Loss	(4,995)	(3,562)	(37,103)	(16,070)
Interest expense, net	(7,264)	(2,497)	(20,546)	(7,482)
Other expense, net	$ 37	$ (1,071)	$ 712	$ (1,653)

SEGMENT REPORTING - Geographic

SEGMENT REPORTING - Geographic (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Segment reporting
Revenue recognition	$ 83,821	$ 52,061	$ 222,153	$ 155,207
Property and equipment, net	42,830		42,830		$ 52,671
Assets held for sale	8,020		8,020
United States
Segment reporting
Revenue recognition	82,851	51,100	219,422	152,007
Property and equipment, net	38,932		38,932		38,564
Canada
Segment reporting
Revenue recognition	970	$ 961	2,731	$ 3,200
Property and equipment, net	3,328		3,328		13,831
Assets held for sale	8,000		8,000
India
Segment reporting
Property and equipment, net	$ 570		$ 570		$ 276